George R. Blumenschein Jr.,, MD

Peer-Reviewed Articles

1. Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Perol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I. A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC. J Thorac Oncol, 2025. e-Pub 2025. PMID: 40516821.
2. Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Saad MB, Pek M, Poh J, Ngeow KC, Tsao A, Cascone T, Negrao MV, Wu J, Blumenschein GR Jr, Heymach JV, Elamin YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clin Res Rep 6(4):100795, 2025. e-Pub 2025. PMID: 40160974.
3. Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein GR, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Perol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study. J Clin Oncol 43(10):1254-1265, 2025. e-Pub 2025.
4. Negrao MV, Paula AG, Molkentine D, Hover L, Nilsson M, Vokes N, Engstrom L, Calinisan A, Briere DM, Waters L, Hallin J, Diao L, Altan M, Blumenschein GR, Skoulidis F, Wang J, Kopetz SE, Hong DS, Gibbons DL, Olson P, Christensen JG, Heymach JV. Impact of Co-mutations and Transcriptional Signatures in Non-Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial. Clin Cancer Res 31(6):1069-1081, 2025. e-Pub 2025. PMID: 39804166.
5. Le X, Patel JD, Shum E, Baik C, Sanborn RE, Shu CA, Kim C, Fidler MJ, Hall R, Elamin YY, Tu J, Blumenschein G, Zhang J, Gibbons D, Gay C, Mohindra NA, Chae Y, Boumber Y, Sabari J, Santana-Davila R, Rogosin S, Herzberg B, Creelan B, Pellini B, Tanvetyanon T, Heeke S, Hernandez M, Gray JE, Saltos A, Heymach JV. A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naive EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial). J Clin Oncol 43(4):403-411, 2025. e-Pub 2025. PMID: 39378386.
6. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Galan-Cobo A, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 635(8038):462-471, 2024. e-Pub 2024. PMID: 39385035.
7. Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
8. Wang T, Navenot JM, Rafail S, Kurtis C, Carroll M, Van Kerckhoven M, Van Rossom S, Schats K, Avraam K, Broad R, Howe K, Liddle A, Clayton A, Wang R, Quinn L, Sanderson JP, McAlpine C, Carozza C, Pimpinella E, Hsu S, Brophy F, Elefant E, Bayer P, Williams D, Butler MO, Clarke JM, Gainor JF, Govindan R, Moreno V, Johnson M, Tu J, Hong DS, Blumenschein GR Jr. Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A *02-eligible patients. Mol Ther Methods Clin Dev 32(2):101265, 2024. e-Pub 2024. PMID: 38872830.
9. Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le X. Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic Targets. JTO Clin Res Rep 5(2):100623, 2024. e-Pub 2024. PMID: 38357092.
10. Nelson BE, Tsimberidou AM, Fu X, Fu S, Subbiah V, Sood AK, Rodon J, Karp DD, Blumenschein G, Kopetz S, Pant S, Piha-Paul SA. A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors. Oncologist 28(12):1100-e1292, 2023. e-Pub 2023. PMID: 37311055.
11. Razak ARA, Wang HM, Chang JY, Ahn MJ, Munster P, Blumenschein G, Solomon B, Lim DW, Hong RL, Pfister D, Saba NF, Lee SH, van Herpen C, Quadt C, Bootle D, Blumenstein L, Demanse D, Delord JP. A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Target Oncol 18(6):853-868, 2023. e-Pub 2023. PMID: 37875771.
12. Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med 29(11):2814-2824, 2023. e-Pub 2023. PMID: 37857711.
13. Weidhaas JB, Hu C, Komaki R, Masters GA, Blumenschein GR, Chang JY, Lu B, Dicker AP, Bogart JA, Garces YI, Narayan S, Robinson CG, Kavadi VS, Greenberger JS, Koprowski CD, Welsh J, Gore EM, MacRae RM, Paulus R, Bradley JD. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun 3(10):2074-2081, 2023. e-Pub 2023. PMID: 37728512.
14. Altan M, Tu J, Milton DR, Yilmaz B, Tian Y, Fossella FV, Mott FE, Blumenschein GR, Stephen B, Karp DD, Meric-Bernstam F, Heymach JV, Naing A. Safety, Tolerability, and Clinical Activity of Selinexor in Combination with Pembrolizumab in Treatment of Metastatic Non-small Cell Lung Cancer. Cancer 129(17):2685-2693, 2023. e-Pub 2023. PMID: 37129197.
15. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
16. Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le X. Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep 4(8):100533, 2023. e-Pub 2023. PMID: 37649681.
17. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and Ipilimumab with Concurrent Stereotactic Radiosurgery for Intracranial Metastases from Non-small Cell Lung Cancer: Analysis of the Safety Cohort for Non-randomized, Open-label, Phase I/II trial. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37402581.
18. Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V, Vaporciyan AA, Blumenschein GR, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L, Gibbons DL, Meric-Bernstam F, Lee JJ, Heymach JV, Hong DS, Heist RS, Awad MM, Skoulidis F. Co-mutations and KRAS G12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov 13(7):1556-1571, 2023. e-Pub 2023. PMID: 37068173.
19. Ferrarotto R, Sousa LG, Feng L, Mott F, Blumenschein G, Altan M, Bell D, Bonini F, Li K, Marques-Piubelli ML, Dal Lago EA, Johnson JJ, Mitani Y, Godoy M, Lee A, Kupferman M, Hanna E, Glisson BS, Elamin Y, El-Naggar A. Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma. J Clin Oncol 41(15):JCO2202221, 2023. e-Pub 2023. PMID: 36898078.
20. Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant Chemotherapy Plus Nivolumab with or without Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Platform NEOSTAR Trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
21. McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. Association of Body Mass Index with the Safety Profile of Nivolumab with or without Ipilimumab. JAMA Oncol 9(1):102-111, 2023. e-Pub 2023. PMID: 36480191.
22. Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand'Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO. Autologous T Cell Therapy for MAGE-A4+ Solid Cancers in HLA-A*02+ Patients: A Phase 1 Trial. Nat Med 29(1):104-114, 2023. e-Pub 2023. PMID: 36624315.
23. Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SH. Final Efficacy Outcomes of Atezolizumab with Chemoradiation for Unresectable NSCLC: The Phase II DETERRED Trial. Lung Cancer 174:112-117, 2022. e-Pub 2022. PMID: 36371941.
24. Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera E. Effect of Dexamethasone on Dyspnoea in Patients with Cancer (ABCD): a Parallel-group, Double-blind, Randomised, Controlled Trial. Lancet Oncol 23(10):1321-1331, 2022. e-Pub 2022. PMID: 36087590.
25. Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP, Blumenschein GR, Tu J, Altan M, Lee P, Liao Z, Lin SH. Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep 3(9):100391, 2022. e-Pub 2022. PMID: 36089921.
26. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR Exon 20-mutant NSCLC: Clinical Efficacy, Resistance Mechanisms, and Impact of Insertion Location on Drug Sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
27. Nagasaka M, Molife C, Cui ZL, Stefaniak V, Li X, Kim S, Lee HY, Beyrer J, Blumenschein G. Generalizability of ORIENT-11 Trial Results to a US Standard of Care Cohort with Advanced Non-small-cell Lung Cancer. Future Oncol 18(16):1963-1977, 2022. e-Pub 2022. PMID: 35354280.
28. Le X, Gleber-Netto FO, Rubin ML, Qing Y, Du R, Kies M, Blumenschein G, Lu C, Johnson FM, Bell D, Lewis J, Zhang J, Feng L, Wilson K, Marcelo-Lewis K, Wang J, Ginsberg L, Gillison M, Lee JJ, Meric-Bernstam F, Mills GB, William WN, Myers JN, Pickering CR. Induction Chemotherapy with or without Erlotinib in Patients with Head and Neck Squamous Cell Carcinoma Amenable for Surgical Resection. Clin Cancer Res. e-Pub 2022. PMID: 35443062.
29. Kindler HL, Novello S, Bearz A, Ceresoli GL, JGJV A, Spicer J, Taylor P, Nackaerts K, Greystoke A, Jennens R, Calabrò L, Burgers JA, Santoro A, Cedrés S, Serwatowski P, Ponce S, Van Meerbeeck JP, Nowak AK, Blumenschein G, Siegel JM, Kasten L, Köchert K, Walter AO, Childs BH, Elbi C, Hassan R, Fennell DA. Anetumab Ravtansine versus Vinorelbine in Patients with Relapsed, Mesothelin-positive Malignant Pleural Mesothelioma (ARCS-M): a Randomised, Open-label Phase 2 Trial. Lancet Oncol 23(4):540-552, 2022. e-Pub 2022. PMID: 35358455.
30. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
31. Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol 40(7):JCO2101113, 2022. e-Pub 2022. PMID: 34550757.
32. Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist 27(2):e194-e198, 2022. e-Pub 2022. PMID: 35641218.
33. Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GR. Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun 30:100514. e-Pub 2022. PMID: 35051703.
34. Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger de Spéville B, Frigault MJ, Olszanski AJ, Lam VK, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM. Phase I Clinical Trial Evaluating the Safety and Efficacy of ADP-A2M10 SPEAR T Cells in Patients with MAGE-A10+ Advanced Non-small Cell Lung Cancer. J Immunother Cancer 10(1), 2022. e-Pub 2022. PMID: 35086946.
35. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein GR, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose Irradiation in Combination with Non-ablative Low-dose Radiation to Treat Metastatic Disease after Progression on Immunotherapy: Results of a Phase II Trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
36. Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein GR, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther 38(8):4581-4591, 2021. e-Pub 2021. PMID: 34241781.
37. Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JV. Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34377884.
38. Tam S, Gajera M, Luo X, Glisson BS, Ferrarotto R, Johnson FM, Mott FE, Gillison ML, Lu C, Le X, Blumenschein GR, Wong MK, Rosenthal DI, Nagarajan P, El-Naggar AK, Midgen MR, Weber RS, Myers JN, Gross ND. Cytotoxic and Targeted Systemic Therapy in Patients with Advanced Cutaneous Squamous Cell Carcinoma in the Head and Neck. Head Neck 43(5):1592-1603, 2021. e-Pub 2021. PMID: 33522021.
39. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Operable Non-small Cell Lung Cancer: The Phase 2 Randomized NEOSTAR Trial. Nat Med. e-Pub 2021. PMID: 33603241.
40. Tam A, Papadimitrakopoulou V, Wistuba I, Lee J, Ensor J, Kim E, Kalhor N, Blumenschein Jr GR, Tsao A, Heymach J, Herbst R, Hicks M, Hong W, Gupta S. The Value of Interventional Radiology in Clinical Trial Teams: Experience from the BATTLE Lung Cancer Trials. Clinical Radiology. e-Pub 2021. PMID: 33268083.
41. Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K. Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol 15(6):803, 2020. e-Pub 2020. PMID: 33108585.
42. Hegde A, Andreev-Drakhlin A, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu M, Busaidy N, Sherman S, Dadu R, Grubbs E, Ali S, Lee J, Elamin Y, Simon G, Blumenschein GR, Papadimitrakopoulou V, Hong D, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open 5(E000799), 2020. e-Pub 2020.
43. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
44. Waterhouse DM, Garon EB, Chandler J, McCleod M, Hussein M, Jotte R, Horn L, Daniel DB, Keogh G, Creelan B, Einhorn LH, Baker J, Kasbari S, Nikolinakos P, Babu S, Couture F, Leighl NB, Reynolds C, Blumenschein G, Gunuganti V, Li A, Aanur N, Spigel DR. Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153. J Clin Oncol:JCO2000131. e-Pub 2020. PMID: 32910710.
45. Hassan R, Blumenschein GR, Moore KN, Santin AD, Kindler HL, Nemunaitis JJ, Seward SM, Thomas A, Kim SK, Rajagopalan P, Walter AO, Laurent D, Childs BH, Sarapa N, Elbi C, Bendell JC. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors. J Clin Oncol 38(16):1824-1835, 2020. e-Pub 2020. PMID: 32213105.
46. Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K. Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol 15(2):163-174, 2020. e-Pub 2020. PMID: 32314268.
47. Bradley JD, Hu C, Komaki RR, Masters GA, Blumenschein GR, Schild SE, Bogart JA, Forster KM, Magliocco AM, Kavadi VS, Narayan S, Iyengar P, Robinson CG, Wynn RB, Koprowski CD, Olson MR, Meng J, Paulus R, Curran WJ, Choy H. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 38(7):JCO1901162, 2020. e-Pub 2020. PMID: 31841363.
48. Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao AS. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. e-Pub 2019. PMID: 31778797.
49. Horn L, Whisenant JG, Wakelee H, Reckamp KL, Qiao H, Leal TA, Du L, Hernandez J, Huang V, Blumenschein GR, Waqar SN, Patel SP, Nieva J, Oxnard GR, Sanborn RE, Shaffer T, Garg K, Holzhausen A, Harrow K, Liang C, Lim LP, Li M, Lovly CM. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer. J Thorac Oncol 14(11):1901-1911, 2019. e-Pub 2019. PMID: 31446141.
50. Saba NF, Blumenschein G, Guigay J, Licitra L, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Li L, Brossart P. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age. Oral Oncol 96:7-14, 2019. e-Pub 2019. PMID: 31422216.
51. Haddad R, Concha-Benavente F, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Kasper S, Vokes EE, Worden F, Saba NF, Tahara M, Jayaprakash V, Lynch M, Li L, Gillison ML, Harrington KJ, Ferris RL. Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. Cancer 125(18):3208-3218, 2019. e-Pub 2019. PMID: 31246283.
52. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML. Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. Clin Cancer Res 25(17):5221-5230, 2019. e-Pub 2019. PMID: 31239321.
53. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JV. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol 37(18):1558-1565, 2019. e-Pub 2019. PMID: 31067138.
54. Negrao MV, Lam VK, Reuben A, Rubin ML, Landry LL, Roarty EB, Rinsurongkawong W, Lewis J, Roth JA, Swisher SG, Gibbons DL, Wistuba II, Papadimitrakopoulou V, Glisson BS, Blumenschein GR, Lee JJ, Heymach JV, Zhang J. PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Non-Small Cell Lung Cancer. J Thorac Oncol 14(6):1021-1031, 2019. e-Pub 2019. PMID: 30780001.
55. Wheatley-Price P, Gadgeel S, Takahashi T, Li X, Dar M, Blumenschein GR. Phase 1b/2 Randomized Study of MEDI-575 in Combination with Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer. Clin Lung Cancer 20(3):e362-e368, 2019. e-Pub 2019. PMID: 30685114.
56. Haddad RI, Massarelli E, Lee JJ, Lin HY, Hutcheson K, Lewis J, Garden AS, Blumenschein GR, William WN, Pharaon RR, Tishler RB, Glisson BS, Pickering C, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Ann Oncol 30(3):471-477, 2019. e-Pub 2019. PMID: 30596812.
57. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. First-In-Human Phase I Study of a Dual mTOR Kinase and DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res 11:10463-10476, 2019. e-Pub 2019. PMID: 31853198.
58. Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer. Oncologist 23(9):1079-1082, 2018. e-Pub 2018. PMID: 29866947.
59. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol 81:45-51, 2018. e-Pub 2018. PMID: 29884413.
60. Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA. Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. Clin Cancer Res 24(12):2771-2779, 2018. e-Pub 2018. PMID: 29563138.
61. Liao Z, Lee JJ, Komaki R, Gomez DR, O'Reilly MS, Fossella FV, Blumenschein GR, Heymach JV, Vaporciyan AA, Swisher SG, Allen PK, Choi NC, DeLaney TF, Hahn SM, Cox JD, Lu CS, Mohan R. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 36(18):JCO2017740720, 2018. e-Pub 2018. PMID: 29293386.
62. Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370). J Thorac Oncol 13(5):682-688, 2018. e-Pub 2018. PMID: 29518553.
63. Vokes EE, Ready N, Felip E, Horn L, Burgio MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D, Waterhouse D, Domine M, Garassino M, Chow LQM, Blumenschein G, Barlesi F, Coudert B, Gainor J, Arrieta O, Brahmer J, Butts C, Steins M, Geese WJ, Li A, Healey D, Crinò L. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol 29(4):959-965, 2018. e-Pub 2018. PMID: 29408986.
64. Reynolds KL, Bedard PL, Lee SH, Lin CC, Tabernero J, Alsina M, Cohen E, Baselga J, Blumenschein G, Graham DM, Garrido-Laguna I, Juric D, Sharma S, Salgia R, Seroutou A, Tian X, Fernandez R, Morozov A, Sheng Q, Ramkumar T, Zubel A, Bang YJ. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer 17(1):646, 2017. e-Pub 2017. PMID: 28899363.
65. Stinchcombe TE, Zhang Y, Vokes EE, Schiller JH, Bradley JD, Kelly K, Curran WJ, Schild SE, Movsas B, Clamon G, Govindan R, Blumenschein GR, Socinski MA, Ready NE, Akerley WL, Cohen HJ, Pang HH, Wang X. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol 35(25):2885-2892, 2017. e-Pub 2017. PMID: 28493811.
66. Harrington KJ, Ferris RL, Blumenschein G, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomized, phase 3 trial. Lancet Oncol 18(8):1104-1115, 2017. e-Pub 2017. PMID: 28651929.
67. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA, Investigators C. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med 376(25):2415-2426, 2017. e-Pub 2017. PMID: 28636851.
68. Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM, Blumenschein G. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 12(3):556-566, 2017. e-Pub 2017. PMID: 27876675.
69. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JV. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672-1682, 2016. e-Pub 2016. PMID: 27789196.
70. Horn L, Wakelee H, Reckamp KL, Blumenschein G, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM. MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology. J Thorac Oncol 11(11S):S256-S257, 2016. e-Pub 2016. PMID: 27969449.
71. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 375(19):1856-1867, 2016. e-Pub 2016. PMID: 27718784.
72. Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. PD2.02 (also presented as P1.44): Phase I/II Trial of X-396, a Novel ALK Inhibitor, in Patients With ALK+ NSCLC. J Thorac Oncol, 2016. e-Pub 2016. PMID: 27676483.
73. Leal T, Wakelee H, Infante J, Blumenschein G, Reckamp K, Carter C, Waqar S, Gockerman J, Lovly C, Dukart G, Harrow K, Liang C, Gibbons J, Horn L. P1.44 (also presented as PD2.02): Phase I/II Trial of X-396, A Novel ALK Inhibitor, in Patients With ALK+ NSCLC: Track: Advanced NSCLC. J Thorac Oncol, 2016. e-Pub 2016. PMID: 27676529.
74. Ganesan P, Ali SM, Wang K, Blumenschein GR, Esmaeli B, Wolff RA, Miller VA, Stephens PJ, Ross JS, Palmer GA, Janku F. Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy. J Clin Oncol 34(5):e34-7, 2016. e-Pub 2016. PMID: 24934779.
75. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. e-Pub 2016. PMID: 26933802.
76. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373(17):1627-39, 2015. e-Pub 2015. PMID: 26412456.
77. Komaki R, Allen PK, Wei X, Blumenschein GR, Tang X, Lee JJ, Welsh JW, Wistuba II, Liu DD, Hong WK. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 92(2):317-324, 2015. e-Pub 2015. PMID: 25968826.
78. Juric D, Dienstmann R, Cervantes A, Hidalgo M, Messersmith W, Blumenschein GR, Tabernero J, Roda D, Calles A, Jimeno A, Wang X, Bohórquez SS, Leddy C, Littman C, Kapp AV, Shames DS, Penuel E, Amler LC, Pirzkall A, Baselga J. Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. Clin Cancer Res 21(11):2462-2470, 2015. e-Pub 2015. PMID: 26034219.
79. Massarelli E, Lin H, Ginsberg LE, Tran HT, Lee JJ, Canales JR, Williams MD, Blumenschein GR, Lu C, Heymach JV, Kies MS, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. e-Pub 2015. PMID: 26025965.
80. Gomez DR, Liao KP, Swisher SG, Blumenschein GR, Erasmus JJ, Buchholz TA, Giordano SH, Smith BD. Time to treatment as a quality metric in lung cancer: Staging studies, time to treatment, and patient survival. Radiother Oncol 115(2):257-263, 2015. e-Pub 2015. PMID: 26013292.
81. Blumenschein GR, Smit EF, Planchard D, Kim DW, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Mazieres J, Kim SW, Baas P, Rappold E, Redhu S, Puski A, Wu FS, Jänne PA. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) . Ann Oncol 26(5):894-901, 2015. e-Pub 2015. PMID: 25722381.
82. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, Investigators K. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018-2028, 2015. e-Pub 2015. PMID: 25891174.
83. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR. A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers. Head Neck 37(5):644-649, 2015. e-Pub 2015. PMID: 24585506.
84. Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S, Bogart J, Hu C, Forster K, Magliocco A, Kavadi V, Garces YI, Narayan S, Iyengar P, Robinson C, Wynn RB, Koprowski C, Meng J, Beitler J, Gaur R, Jr CW, Choy H. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187-199, 2015. e-Pub 2015.
85. Gold KA, Lee JJ, Harun N, Tang X, Price J, Kawedia JD, Tran HT, Erasmus JJ, Blumenschein GR, William WN, Wistuba II, Johnson FM. A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer. Oncologist 19(10):1040-1, 2014. e-Pub 2014. PMID: 25170013.
86. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget 5(19):8937-8946, 2014. e-Pub 2014. PMID: 25313136.
87. Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324. Radiother Oncol 112(1):30-6, 2014. e-Pub 2014. PMID: 25042878.
88. Hellmann MD, Chaft JE, Jr WW, Rusch V, Pisters KM, Kalhor N, Pataer A, Travis WD, Swisher SG, Kris MG, Collaborative Group UOTMALC. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncology 15(1):42-50, 2014. e-Pub 2014.
89. Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SM. Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res 19(24):6967-6975, 2013. e-Pub 2013. PMID: 24166906.
90. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 31(32):4105-14, 2013. e-Pub 2013. PMID: 24101053.
91. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378-384, 2013. e-Pub 2013. PMID: 23810431.
92. Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small cell lung cancer (NSCLC). Ann Oncol 24(9):2382-9, 2013. e-Pub 2013. PMID: 23788751.
93. Gonzalez-Angulo AM, Blumenschein GR. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39(4):313-20, 2013. e-Pub 2013. PMID: 23218708.
94. Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol 8(5):658-661, 2013. e-Pub 2013. PMID: 23584298.
95. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of Image-Guided Transthoracic Core Needle Biopsy in the BATTLE Lung Trial. J Thorac Oncol 8(4):436-42, 2013. e-Pub 2013. PMID: 23442309.
96. Seiwert T, Sarantopoulos J, Kallender H, McCallum S, Keer HN, Blumenschein G. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 31(2):417-424, 2013. e-Pub 2013. PMID: 22918720.
97. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24(1):220-5, 2013. e-Pub 2013. PMID: 22898037.
98. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 2013. e-Pub 2013. PMID: 22736407.
99. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-90, 2013. e-Pub 2013. PMID: 23091115.
100. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pre-treated NSCLC patients from the BATTLE trial. J Thorac Oncol 7(11):1645-52, 2012. e-Pub 2012. PMID: 23059780.
101. Blumenschein GR, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol 7(9):1406-16, 2012. e-Pub 2012. PMID: 22743295.
102. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30(26):3287-96, 2012. e-Pub 2012. PMID: 22869872.
103. Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Brandon Gunn G, Lewin JS, Steinhaus GD, Sturgis EM. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck 34(9):1255-62, 2012. e-Pub 2012. PMID: 22009800.
104. Blumenschein GR Jr. Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Invest New Drugs, 2012. e-Pub 2012. PMID: 21987350.
105. Belani CP, Goss G, Blumenschein G. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 38(3):173-84, 2012. e-Pub 2012. PMID: 21715100.
106. Pataer A, Kalhor N, Correa AM, Raso MG, Erasmus JJ, Kim ES, Behrens C, Lee JJ, Roth JA, Stewart DJ, Vaporciyan AA, Wistuba H, Swisher SG, Blumenschein GR. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 7((5)):825-32, 2012. e-Pub 2012. PMID: 22481232.
107. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 2012. e-Pub 2012. PMID: 22374333.
108. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis G. Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. J Natl Cancer Inst 104(3):228-39, 2012. e-Pub 2012. PMID: 22247021.
109. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-2111, 2011. e-Pub 2011. PMID: 21892101.
110. Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol 68(3):703-12, 2011. e-Pub 2011. PMID: 21140147.
111. Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L, Study Investigators MNPI. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 22(9):2057-67, 2011. e-Pub 2011. PMID: 21321086.
112. Adjei AA, Blumenschein GR, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer 12(4):212-7, 2011. e-Pub 2011. PMID: 21726819.
113. Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II Study of Cetuximab in Combination with Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324. J Clin Oncol 29(17):2312-8, 2011. e-Pub 2011. PMID: 21555682.
114. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov 1(1):44-53, 2011. e-Pub 2011. PMID: 22586319.
115. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 2011. e-Pub 2011. PMID: 20094773.
116. Blumenschein GR, Reck M, Fossella F, Stewart DJ, Lathia C, Peña C. Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark 10(6):287-98, 2011. e-Pub 2011. PMID: 22820084.
117. Komaki R, Wei X, Allen PK, Liao Z, Milas L, Cox JD, O'Reilly MS, Chang JY, McAleer MF, Jeter M, Blumenschein GR, Kies MS. Phase I study of celecoxib with concurrent irinotecan, cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer. Front Oncol 1:52, 2011. e-Pub 2011. PMID: 22649768.
118. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II Study of Dasatinib in Patients with Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 28(30):4609-15, 2010. e-Pub 2010. PMID: 20855820.
119. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer 116(10):2409-15, 2010. e-Pub 2010. PMID: 20225329.
120. Liao ZX, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 76(3):775-81, 2010. e-Pub 2010. PMID: 19515503.
121. Ross HJ, Blumenschein GR, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 16(6):1938-49, 2010. e-Pub 2010. PMID: 20215545.
122. Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16(1):279-90, 2010. e-Pub 2010. PMID: 20028752.
123. Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients with Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 27(26):4274-80, 2009. e-Pub 2009. PMID: 19652055.
124. Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B. Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol 127(8):1074-5, 2009. e-Pub 2009. PMID: 19667357.
125. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G, Johnson FM, Green S, Gualberto A. Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15):2516-22, 2009. e-Pub 2009. PMID: 19380445.
126. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference opportunities for combination therapy. J Thorac Oncol 3((6 Suppl 2)):S107-12, 2008. e-Pub 2008. PMID: 18520291.
127. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. J Thorac Oncol 3(4):351-7, 2008. e-Pub 2008. PMID: 18379352.
128. Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. A Randomized Phase III Trial Comparing Bexarotene (L1069-48) /Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (SPIRIT II). J Clin Oncol 26(11):1879-85, 2008. e-Pub 2008. PMID: 18398153.
129. Husain A, Blumenschein G, Esmaeli B. Treatment and Outcomes for Metastatic Sebaceous Cell Carcinoma of the Eyelid. Int J Dermatol 47(3):276-9, 2008. e-Pub 2008. PMID: 18289332.
130. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-7, 2008. e-Pub 2008. PMID: 17960324.
131. Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31(11):1645-52, 2007. e-Pub 2007. PMID: 18059220.
132. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-85, 2007. e-Pub 2007. PMID: 17418967.
133. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 2006. e-Pub 2006. PMID: 16640804.
134. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Jr, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106(2):441-7, 2006. e-Pub 2006. PMID: 16342067.
135. Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer. Cancer 104(11):2449-56, 2005. e-Pub 2005. PMID: 16258975.
136. Robert F, Blumenschein G, Herbst RS, Fossella FV, Tseng J, Saleh MN, Needle M. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23(36):9089-96, 2005. e-Pub 2005. PMID: 16301597.
137. Liao Z, Komaki R, Milas L, Yuan C, Kies M, Chang JY, Jeter M, Guerrero T, Blumenschein G, Smith CM, Fossella F, Brown B, Cox JD. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res 11(9):3342-8, 2005. e-Pub 2005. PMID: 15867233.
138. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler A. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(11):2544-55, 2005. e-Pub 2005. PMID: 15753462.
139. Tran HT, Blumenschein GR, Jr, Lu C, Meyers CA, Papadimitrakopoulou V, Fossella FV, Zinner R, Madden T, Smythe LG, Puduvalli VK, Munden R, Truong M, Herbst RS. Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors. Cancer Chemother Pharmacol 54(4):308-314, 2004. e-Pub 2004. PMID: 15184994.
140. Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR, Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58(5):1369-77, 2004. e-Pub 2004. PMID: 15050312.
141. Papadimitrakopoulou VA, Ginsberg LE, Garden AS, Kies MS, Glisson BS, Diaz EM, Jr, Clayman G, Morrison WH, Liu DD, Blumenschein G, Jr, Lippman SM, Schommer D, Gillenwater A, Goepfert H, Hong WK. Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma. Cancer 98(10):2214-23, 2003. e-Pub 2003. PMID: 14601092.
142. Johnson FM, Kurie JM, Peeples BO, Lee JJ, Feng L, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer 5(1):40-5, 2003. e-Pub 2003. PMID: 14596703.
143. Johnson FM, Kurie JM, Peeples BO, Pisters KM, Fossella FV, Papadimitrakopoulou VA, Blumenschein GR, Komaki R, Glisson BS. Dose-dense therapy with a novel irinotecan regimen for small-cell lung cancer. Oncology (Williston Park) 17(7 Suppl 7):17-21, 2003. e-Pub 2003. PMID: 12886869.
144. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Meyers CA, Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T, Hong WK. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. J Clin Oncol 20(22):4440-7, 2002. e-Pub 2002. PMID: 12431966.
145. Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer 95(2):340-53, 2002. e-Pub 2002. PMID: 12124835.
146. Esmaeli B, Naderi A, Hidaji L, Blumenschein G, Prieto VG. Merkel cell carcinoma of the eyelid with a positive sentinel node. Arch Ophthalmol 120(5):646-648, 2002. e-Pub 2002. PMID: 12003618.

Invited Articles

1. Blumenschein GR. Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC). Invest New Drugs 30(4):1802-11, 2012. e-Pub 2012. PMID: 21987350.
2. Blumenschein G. Insulin-like growth factor receptor. J Thorac Oncol 11 Suppl(4):S1799-800, 2011. e-Pub 2011. PMID: 22005535.
3. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs 20(6):859-69, 2011. e-Pub 2011. PMID: 21534718.
4. Blumenschein G. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol 3((6 Suppl 2)):S124-7, 2008. e-Pub 2008. PMID: 18520294.
5. Blumenschein G Jr, Heymach JV. Angiogenesis Inhibitors for lung Cancer: Clinical developments and future directions. J Thorac Oncol 1(7)(7):744-748, 2006. e-Pub 2006. PMID: 17409952.
6. Blumenschein GR Jr, Herbst RS. Integration of targeted therapies in gemcitabine chemotherapy regimens. Clin Lung Cancer 4(4):217-23, 2003. e-Pub 2003. PMID: 14624709.

Review Articles

1. Villaruz LC, Blumenschein GR, Otterson GA, Leal TA. Emerging Therapeutic Strategies for Enhancing Sensitivity and Countering Resistance to Programmed Cell Death Protein 1 or Programmed Death-ligand 1 Inhibitors in Non-small Cell Lung Cancer. Cancer 129(9):1319-1350, 2023. e-Pub 2023. PMID: 36848319.
2. Molife C, Brnabic A, Stefaniak VJ, Belger MA, Gruver K, Chen JV, Souri S, Blumenschein GR. Sintilimab plus Chemotherapy for First-line Treatment of Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer: Network Meta-analysis. Immunotherapy 15(4):293-309, 2023. e-Pub 2023. PMID: 36748406.
3. Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H, Olson A, Blumenschein G, Hong DS, Shpall EJ, Kebriaei P. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant 26(10):1759-1769, 2020. e-Pub 2020. PMID: 32623078.
4. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome. Zhongguo Fei Ai Za Zhi 16(4):C9-20, 2013. e-Pub 2013. PMID: 23601304.
5. Raghav KP, Gonzalez-Angulo AM, Blumenschein GR. Role of HGF/MET axis in resistance of lung cancer to contemporary management. Transl Lung Cancer Res 1(3):179-193, 2012. e-Pub 2012. PMID: 25806180.
6. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome. J Thorac Oncol 6(10):1763-1773, 2011. e-Pub 2011. PMID: 21876456.
7. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):4441s-4445s, 2006. e-Pub 2006. PMID: 16857825.
8. Komaki R, Janjan NA, Ajani JA, Lynch PM, Fairweather JS, Raijman I, Blumenschein GR, Ho L, Pisters PW, Feig BW, Walsh GL, Pazdur R. Phase I Study of Irinotecan and Concurrent Radiation Therapy for Upper GI Tumors. Oncology (Williston Park) 14(12 Suppl 14):34-7, 2000. e-Pub 2000. PMID: 11200147.

Other Articles

1. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature 639(8054):E19, 2025. PMID: 40016449.
2. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 15(1):5621, 2024. PMID: 38965214.

Abstracts

1. Elamin Y, Gandhi S, Han X, Heeke S, Sui D, Antonoff MB, Gibbons DL, Le X, Negrao M, Lam VK, Altan M, Tran H, Tu J, Gay CM, Byers L, Cascone T, Blumenschein GR, Chang J, Vaporciyan A, Liao Z, Swisher S, Zhang J, Lee J, Wu J, Heymach J. Final Analysis of Brighstar: LCT With Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC. 2025 IASLC World Conference on Lung Cancer, 2025. e-Pub 2025.
2. Altan M, Beckham T, Song J, Welsh J, Guha-Thakurta N, Carter B, Blumenschein GR, Elamin Y, Tang C, Ghia A, Yeboa D, McAleer MF, Chung C, McGovern SL, Wang C, Martin T, Perni S, Jiang W, De BS, Wefel JS, Wang Y, Hicks J, Kim YSB, Weinberg J, Briere TM, Le X, Cascone T, Vailati Negrao M, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Phase I/II Study of Nivolumab and Ipilimumab With Concurrent Stereotactic Radiosurgery for Intracranial Metastases From NSCLC. 2025 IASLC World Conference on Lung Cancer, 2025. e-Pub 2025.
3. Amaria R, Kopetz S, Morelli MP, Blumenschein GR, Altan M, Sanber K, Jazaeri A, Davies M, Diab A, Glitza I, McQuade J, Ikeguchi A, Tawbi H, Bernatchez C, Forget MA, Haymaker C, Wong K, Tobin E, Bednson M, Truppel-Hartmann A. A Phase 1/2 Study of KSQ-004EX: Autologous Tumor Infiltrating Lymphocytes, Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients with Select Advanced Solid Tumors. 2025 ASCO Annual Meeting, 2025. e-Pub 2025.
4. Lisberg A, Ahn MJ, Kitazono S, Cho BC, Blumenschein GR, Shum E, Pons-Tostivint E, Goto Y, Yoh K, Paz-Ares LG, Heist RS, Baas P, Planchard D, Perol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Sands J. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05, 2024 ASCO Annual Meeting, Abstract # 8593. J Clin Oncol 42(16 S), 2024. e-Pub 2024.
5. Johnson ML, Burns TF, Thompson JR, Spira AI, Alexander M, Blumenschein GR Jr, Michalski J, Bilic S, Teh A, Lai KC, McGann S, Chalk H, Haystrand L, Wu TH, Gallant G, Heist RS. MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study - 2024 ASCO Annual MeetingAbstract#8558. J Clin Oncol 24(16 S), 2024. e-Pub 2024.
6. Nardo M, Gouda MA, Ahmed J, Barreto CMN, Nelson BE, Araujo DM, Blumenschein GR, Tsimberidou AM, Piha-Paul SA, Dumbrava EE, Hong DS. Predictors of Survival Outcomes in Patients (pts) with Advanced Solid Tumors Treated with Cellular Therapies in Early Clinical Trials. 2023 ASCO Annual Meeting, J Clin Oncol 41(16), 2023. e-Pub 2023.
7. Spira AI, Johnson ML, Blumenschein GR, Burns TF, Thompson JR, Deshpande A, Comb WC, Fiske B, Gallant G, Heist RS. Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-drug Conjugate (ADC) MYTX-011 in Subjects with Non-small Cell Lung Cancer. 2023 ASCO Annual Meeting, J Clin Oncol 41(16), 2023. e-Pub 2023.
8. Wang T, Navenot JM, Rafail S, Carroll M, Wang R, McAlpine C, Biswas S, Brophy F, Elefant E, Bayer P, McGuigan S, Williams D, Blumenschein G, Butler M, Clarke JM, Gainor JF, Govindan R, Moreno V, Tu J, Hong DS. Identifying Mage-A4-Positive Tumors for Spear T-Cell Therapies in HLA-A*02-Eligible Patients. AACR Annual Meeting 2022, Poster Presentation, 2022. e-Pub 2022.
9. Wang T, Navenot JM, Rafail S, Carroll M, Wang R, McAlpine C, Biswas S, Brophy F, Elefant E, Bayer P, McGuigan S, Williams D, Blumenschein G, Butler M, Clarke JM, Gainor JF, Govindan R, Moreno V, Tu J, Hong DS. Identifying Mage-A4-Positive Tumors for Spear T-Cell Therapies in HLA-A*02-Eligible Patients, Poster Presentation. Connective Tissue Oncology Society CTOS 2022, 2022. e-Pub 2022.
10. Hong D, Clarke J, Asch A, Charlson J, Johanns T, Calvo E, Boni V, de Miguel M, Moreno V, Lawrence D, Butler M, Zugazagoitia J, Lin Q, Norry E, Blumenschein G. Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8á co-receptor and an affinity optimized TCR targeting MAGE-A4. ESMO Congress 2021, 2021. e-Pub 2021.
11. Blumenschein G, Eggert T, Shetty A, Janet-amsbury M, Kouros-Mehr, H, Gupta V, Tiso S, Salvati M, Boyer M. Targeting the Tumor Neovasculature in Lung Cancer: A Phase 1 Study of AMG 160 in Subjects with Non-Small Cell Lung Cancer". World Conference on Kung ( WCLC), 2021. e-Pub 2021.
12. Fitzgerald J, Blumenschein G, Vlock D, Zhang J, Murray J, Motta M, Bardwell P. (801) PRIME™ IL-15 (RPTR-147): Preliminary clinical results and biomarker analysis from a first-in-human Phase 1 study of IL-15 loaded peripherally-derived autologous T cell therapy in solid tumor patients. SITC Annual Meeting, 2020. e-Pub 2020.
13. Pant S, Shah A, Msaouel P, Campbell M, Tu S, Gao J, Blumenschein Jr GR, Mott F, Le X, Altan M, Meric-Bernstam F, Yap T, Subbiah V, Rodon J, Glasmacher J, Mulder I, Chisamore M, Stevenson A, Tannir N. Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs). SITC Annual Conference, 2020. e-Pub 2020.
14. Sepesi B, Corsini EM, Weissferdt A, Pataer A, Leung CH, Lin H, Le X, Mott F, Fossella F, Altan M, Tsao A, Skoulidis F, Blumenschein G, Kurie J, Zhang J, Glisson B, Lu C, Elamin Y, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Gibbons DL, Heymach JV, Cascone T. Combined Neoadjuvant Chemo-Immunotherapy Therapy Achieves Superior Downstaging of Resectable Non-Small Cell Lung Cancer as Compared to Chemotherapy, Mono or Dual Immunotherapy. SITC Annual Conference, 2020. e-Pub 2020.
15. Pant S, Shah A, Msaouel P, Campbell M, Tu S, Gao J, Blumenschein Jr GR, Mott F, Le X, Altan M, Meric-Bernstam F, Yap T, Subbiah V, Rodon J, Glasmacher J, Mulder I, Chisamore M, Stevenson A, Tannir N. A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patient's refractory to immune checkpoint inhibitors. SITC Annual Conference, 2020. e-Pub 2020.
16. Blumenschein Jr GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman M, Heymach J, Govindan R, Bachier C, Doger de Spéville B, Frigault M, Olszanski A, Lam V, Hyland N, Navenot J, Fayngerts S, Bai J, Norry E, Fracasso P. Phase I clinical trial evaluating the safety of ADP-A2M10 SPEAR T-cells in patients with MAGE-A10+ advanced non-small cell lung cancer. SITC Annual Conference, 2020. e-Pub 2020.
17. Patel M, Luke J, Hamilton E, Chmielowski B, Blumenschein G, Kindler H, Bahadur S, Santa-Maria C, Koucheki J, Sun J, Kaul S, Chen F, Zhang X, Muth J, Kaminker P, Moore P, Sumrow B, Ulahannan S. A Phase 1 Evaluation of Tebotelimab, a Bispecific PD-1 x LAG-3 DART® Molecule, in Combination with Margetuximab in Patients with Advanced HER2+ Neoplasms. SITC Annual Conference, 2020. e-Pub 2020.
18. Sepesi B, Corsini EM, Weissferdt A, Pataer A, Leung CH, Lin H, Le X, Mott F, Fossella F, Altan M, Tsao A, Skoulidis F, Blumenschein G, Kurie J, Zhang J, Glisson B, Lu C, Elamin Y, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Gibbons DL, Heymach JV, Cascone T. Combined Neoadjuvant Chemo-Immunotherapy Therapy Achieves Superior Downstaging of Resectable Non-Small Cell Lung Cancer as Compared to Chemotherapy, Mono or Dual Immunotherapy. 28th European Conference on General Thoracic Surgery, 2020. e-Pub 2020.
19. Hanna G, Jung S, Niu J, Bishop M, Chu R, Klebanoff C, Adhikary S, Kirtane K, Massarelli E, Lee S, Rodriguez K, Blumenschein G, Astrow S. KITE-439: A Phase 1 Study of HPV16 E7 T Cell Receptor–Engineered T Cells in Patients With Relapsed/Refractory HPV16–Positive Cancers. American Society of Clinical Oncology - 56th Annual Meeting, 2020. e-Pub 2020.
20. Luke J, Patel M, Hamilton E, Chmielowski B, Ulahannan S, Kindler H, Bahadur S, Clingan P, Mallesara G, Weickhardt A, Currence S, Xu L, Kaul S, Chen F, Moore P, Bonvini E, Sumrow B, Blumenschein G. A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD‑1 and LAG‑3, in patients with unresectable or metastatic neoplasms. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
21. Elamin Y, Gandhi S, Antonoff M, Mott F, Gibbons D, Le X, Negrao M, Sepesi B, Karam J, Cascone T, Wang L, Blumenschein G, Glisson B, Tsao A, Heymach J. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naïve ALK-rearranged advanced NSCLC. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
22. Kirtana K, Massarelli E, Hanna G, Klebanoff C, Blumenschein G, Bishop M, Lee S, Niu J, Adhikary S, Astrow S, Rodgriguez K, Chu R, Jung A. KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
23. Blumenschein Jr G, Davar D, Gutierrez R, Segal N, Johnson M, Dar M, Marshall S. A phase I/II first-in-human study of a novel anti-MAGE-A4 TCR/anti-CD3 bispecific (IMC-C103C) as monotherapy and in combination with atezolizumab in HLA-A*02:01-positive patients with MAGE-A4-positive advanced solid tumors (IMC-C103C-101). ASCO Virtual Scientific Program, 2020. e-Pub 2020.
24. McQuade J, Hammers H, Furberg H, Engert A, Andre A, Blumenschein G, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone D, Thomas J, Hennicken D, Zoffoli R, Reshef D, Coffey M, Motzer R. Safety of weight-based dosing of nivolumab with or without ipilimumab by body mass index (BMI) stratified by sex across 14 CheckMate clinical trials. ASCO Virtual Scientific Program, 2020. e-Pub 2020.
25. Arnaldez F, Aggarwal C, Currence S, Baughman J, Moore P, Blumenschein Jr G, Wigginton J, Ferris R. Phase 2/3 open-label trial of enoblituzumab in combination with MGA012, with and without chemotherapy, in the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma. SITC Annual Conference, National Harbor, MD, 2019. e-Pub 2019.
26. Leal T, Wakelee H, Reckamp KL, Chiappori A, Oxnard GR, Waqar SN, Patel SP, Blumenschein GR, Neal JW, Harrow K, Holzhausen A, Selvaggi G, Zhou J, Horn L. Long term efficacy and safety of ensartinib in pre-treated anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC) patients (eXalt2). IASLC 2019 Latin America Conference on Lung Cancer (LALCA 2019), 2019. e-Pub 2019.
27. Ferris R, Licitra L, Fayette J, Even C, Blumenschein Jr G, Harrington K, Guigay J, Vokes E, Saba N, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas A, Concha-Benavente F, Lynch M, Li L, Gillison M. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. AACR Clinical Cancer Research, Atlanta, GA, 2019. e-Pub 2019.
28. Hegde A, Le H, Liu S, Hess K, Cabanillas M, Hu M, Busaidy N, Sherman S, Simon G, Blumenschein GR, Papadimitrakopoulou VA, Hong DS, Meric-Bernstam F, Heymach J, Subbiah V. Responsiveness to immune checkpoint inhibitors in RET dependent cancers. 2019 AACR Annual Meeting. Cancer Res 79(13 Supplement):Abstract 4997, 2019. e-Pub 2019.
29. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Camidge DR, Skoulidis F, Doebele R, Gaspar LE, Gibbons DL, Karam J, Kavanagh BD, Palma DA, Louie AV, Tsao A, Sepesi B, Swisher SG, Heymach J. Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial. ASTRO Annual Meeting, San Antonio, TX, 2018. e-Pub 2018.
30. Thor M, Deasy JO, Hu C, Choy H, Komaki RU, Masters G, Blumenschein GR, Forster KM, Oh JH, Kavadi VS, Narayan S, Timmerman RD, Robinson CG, Greenberger JS, Biggs D, Augspurger M, Meng J, Bradley JD. The Role of Heart-Related Dose-Volume Metrics on Overall Survival in the RTOG 0617 Clinical Trial. ASTRO Annual Meeting, San Antonio, TX, 2018. e-Pub 2018.
31. Weissferdt A, Sepesi B, Pataer A, Kalhor N, Moran C, William W, Le X, Glisson B, Skoulidis F, Blumenschein G, Zhang J, Altan M, Rice D, Mehran R, Lee J, Vaporciyan A, Gibbons D, Swisher S, Heymach J, Cascone T. 1928P - Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). ESMO Annual Meeting, Munich, Germany, 2018. e-Pub 2018.
32. Wakelee H, Reckamp K, Leal T, Patel S, Blumenschein G, Shum E, Nieva J, Oxnard G, Sanborn R, Waqar S, Zeman K, Dukart G, Harrow K, Liang C, Holzhausen A, Horn L. 1496P - Intracranial Activity of Ensartinib in Patients with Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC). ESMO Annual Meeting, Munich, Germany, 2018. e-Pub 2018.
33. Lam V, Hong D, Heymach J, Blumenschein G, Butler M, Johnson M, Creelan B, Gainor J, Govindan R, Mudad R, Neal J, Brophy F, Fang F, Hyland N, Holdich T, Trivedi T, Norry R, Amado R. LBA38 - Safety and Anti-Tumor Effects of MAGE-A10c796 TCR T-cells in Two Clinical Trials. ESMO Annual Meeting, Munich, Germany, 2018. e-Pub 2018.
34. Lin S, Lin X, Clay D, Yao L, Mok I, Gomez D, Kurie J, Simon G, Blumenschein GR, Young J, Phan S, Sandler A, Papadimitrakopoulou V, Heymach J, Tsao A. OA01.06 DETERRED: PHASE II TRIAL COMBINING ATEZOLIZUMAB CONCURRENTLY WITH CHEMORADIATION THERAPY IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER. IASLC World Lung Annual Meeting, Toronto, Canada, 2018. e-Pub 2018.
35. Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Prado E, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Byers L, Altan M, Elamin Y, Lanman R, Raymond V, Tsao A, Gibbons D, Fossella F, Zhang J, Heymach J. P1.13-37 Clinical Evaluation of Plasma-based (CFDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-small Cell Lung Cancer. IASLC World Lung Annual Meeting, Toronto, Canada, 2018. e-Pub 2018.
36. Tran H, Lam V, Vasquez M, Hong L, Colen R, Elshafeey N, Hassan I, Prado E, Papadimitrakopoulou V, Blumenschein G, Carter B, Simon G, Byers L, Altan M, Elamin Y, Lanman R, Raymond V, Tsao A, Gibbons D, Fossella F, Zhang J, Heymach J. P1.13-03 ENSARTINIB TREATMENT BEYOND DISEASE PROGRESSION IN STAGE IV ALK+ NON-SMALL CELL LUNG CANCER. IASLC World Lung Annual Meeting, Toronto, Canada, 2018. e-Pub 2018.
37. Heymach J, Negrao M, Robichaux J, Carter B, Patel A, Altan M, Gibbons D, Fossella F, Simon G, Lam V, Blumenschein GR, Tsao A, Kurie J, Mott F, Jenkins D, Mack D, Feng L, Roeck B, Yang Z, Papadimitrakopoulou V, Elamin Y. OA02.06 A PHASE II TRIAL OF POZIOTINIB IN EGFR AND HER2 EXON 20 MUTANT NON-SMALL CELL LUNG CANCER (NSCLC). IASLC World Lung Annual Meeting, Toronto, Canada, 2018. e-Pub 2018.
38. Lam VK, Hong DS, Heymach J, Blumenschein GR, Creelan BC, Bradbury PA, Butler MA, Gainor JF, Govindan R, Johnson ML, Mudad R, Sullivan RJ, Brophy F, Hyland N, Chagin K, Holdich T, Norry E, Amado RG. Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials. ASCO Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
39. Horn L, Infante J, Reckamp K, Blumenschein GR, Leal T, Waqar S, Gitlitz B, Sanborn R, Whisenant J, Du L, Neal J, Gockerman J, Dukart G, Harrow K, Liang C, Gibbons J, Holzhausen A, Lovly C, Wakelee H. Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study. AACR Clinical Cancer Research, Atlanta, GA, 2018. e-Pub 2018.
40. Saba NF, Blumenschein GR, Guigay J, Licitra LF, Fayette J, Harrington KJ, Kiyota N, Gillison ML, Ferris RL, Jayaprakash V, Lynch MJ, Li L, Brossart P. Nivolumab (nivo) vs investigator’s choice (IC) in patients (pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Analysis of CheckMate 141 by age. ASCO Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
41. Kebriaei P, Klebanoff CA, Creelan BC, Hong DS, Blumenschein GR, Drakaki A, Tewari A, Thomrongsith L, Jiang Y, Jain RK. A phase 1 multicenter study evaluating the safety and efficacy of MHC class II-restricted MAGE-A3/A6 T-cell receptor engineered T cells (KITE-718) in patients with advanced cancers. ASCO Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
42. Ferris RL, Blumenschein GR, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad RI, Rordorf T, Kiyota N, Tahara M, Lynch M, Li L, Gillison M. Two-year Update from CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups. ASTRO Annual Meeting, San Antonio, TX, 2018. e-Pub 2018.
43. Senra J, Villalobos P, Mino B, Solis L, Behrens C, Sanderson JP, Saini M, Gerry AB, Pumphrey NJ, Maroto M, Sepesi B, Hwu P, Hong DS, Mittendorf EA, Blumenschein G, Wistuba II, Binder-Scholl G, Amado R. 2562 / 21 - Affinity-enhanced T-cell receptor (TCR) for adoptive T-cell therapy targeting MAGE-A4. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
44. Ferris RL, Blumenschein GR Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML. CT116 - Nivolumab (Nivo) vs investigator’s choice (IC) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): 2-yr outcomes in the overall population and PD-L1 subgroups of CheckMate 141. AACR Annual Meeting, Chicago, IL, 2018. e-Pub 2018.
45. Blumenschein G Jr. Treatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes. ESMO Annual Meeting, Barcelona, Spain, 2017. e-Pub 2017.
46. Haddad R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L, Kasper S, Vokes E, Worden F, Saba N, Tahara M, Concha-Benavente F, Monga M, Lynch M, Li L, Shaw J, Gillison M, Harrington K, Ferris R. Treatment Beyond Progression with Nivolumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in the Phase 3 Checkmate 141 Study. American Association for Cancer Research - 108th Annual Meeting, 2017. e-Pub 2017.
47. Blumenschein G Jr. Nivolumab vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): treatment effect on clinical outcomes by best overall response in checkmate 141. ESMO Annual Meeting, Barcelona, Spain, 2017. e-Pub 2017.
48. Ferris R, Blumenschein G, Harrington K, Fayette J, Guigay J, Colevas A, Licitra L, Kasper S, Even C, Worden F, Saba N, Vokes E, Ho C, Concha-Benavente F, Greenawalt D, Jin C, Lynch M, Tahara M, Haddad R, Monga M, Kao H, Gillison M. Tumor-associated immune cell (TAIC) PD-L1 expression and peripheral cytokine profiling: Analyses from CheckMate 141. American Association for Cancer Research - 108th Annual Meeting 77(13), 2017. e-Pub 2017.
49. Ferris R, Licitra L, Fayette J, Even C, Blumenschein GR, Harrington K, Guigay J, Vokes E, Saba N, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Monga M, Zhu J, Colevas A, Gillison M. Nivolumab (Nivo) vs investigator’s choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. ASCO 53rd Annual Meeting, 2017. e-Pub 2017.
50. Gillison M, Blumenschein GR, Fayette J, GuigayJ, Colevas A, Licitra L, Harrington K, Kasper S, Vokes E, Even C, Worden F, Saba N, Docampo L, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Kopit J, Ferris R. Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy. ASCO 53rd Annual Meeting, 2017. e-Pub 2017.
51. Licitra L, Ferris RL, Blumenschein G Jr, Harrington KJ, Guigay J, Kasper S, Saba MF, Haddad R, Kiyota N, Monga M, Lynch M, Li L, Gillison ML, Fayette J. Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy, 2017. e-Pub 2017.
52. Ferris R, Blumenschein G, Harrington K, Fayette J, Guigay J, Colevas A, Licitra L, Vokes E, Gillison M, Even C, Ho C, Tahara M, Haddad, Lynch M, Monga M, Bandyopadhyay S, Jabado O, Kao H. Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141. American Association for Cancer Research 77(13), 2017. e-Pub 2017.
53. Gillison M, Harrington K, Ferris R, Guigay J, Blumenschein Jr G, Fayette J, Colevas A, Kiyota N, Shaw J, Monga M, Lynch M, Kopit J, Taylor F, DeRosa M, Morrissey L, Cocks K, Saba N. Nivolumab versus Investigator’s Choice Therapy Among Patients with Human Papillomavirus (HPV)-Associated Squamous Cell Carcinoma of the Head and Neck (SCCHN): Updated Results from CheckMate 141. American Head & Neck Society - 2017 Annual Meeting (See COSM), 2017. e-Pub 2017.
54. Komaki R, Allen P, Wei S, Blumenschein G, Tang XM, Lee J, Welsh J, Wistuba I, Liu D, Meyn R, Hong WK. Final Results of Prospective Phase II Study of Adding Erlotinib to Chemoradiation for patients with Stage III Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 12(15), 2017. e-Pub 2017.
55. Horn L, Patel SP, Blumenschein GR Jr, Gitlitz BJ, Waqar SN, Oxnard GR, Brzezniak CE, Dukart G, Tan F, Harrow K, Liang C, Reckamp KL. CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts). ASCO Annual Meeting 2017, 2017. e-Pub 2017.
56. Ferrarotto R, Glisson BS, Jr WW, Kies MS, Blumenschein GR Jr, Hong DS, Piha-Paul SA, Jain D, Painter J, Hess KR, Colen RS, Mendoza TR, Heymach J, Meric-Bernstam F, Naing A. Phase II Study for the Evaluation of Efficacy of Pembrolizumab in Patients with Cutaneous Squamous Cell Carcinoma. ASCO Annual Meeting 2017, 2017. e-Pub 2017.
57. Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington K, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Monga M, Zhu J, Colevas AD, Gillison ML. Nivolumab vs Investigator’s Choice in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate141 by Prior Cetuximab Use. ASCO Annual Meeting 2017, 2017. e-Pub 2017.
58. Lin SJ, Lin Y, Price J, Parker M, Gomez DR, Welsh JW, Komaki R, Kurie JM, Simon GR, Blumenschein GR Jr, Young JA, S-C P, Sandler A, Papadimitrakopoulou V, Heymach J, Tsao AS. DETERRED: PD-L1 Blockade to Evaluate the Safety of Lung Cancer Therapy using Carboplatin, Paclitaxel, and Radiation combined with MPDL3280A (atezolizumab). ASCO Annual Meeting 2017, 2017. e-Pub 2017.
59. Jr WW, Feng L, Kies MS, Ahmed S, Blumenschein GR Jr, Glisson BS, Massarelli E, Johnson FM, Lu C, Papadimitrakopoulou V, Gold KA, Theriault RL, Heymach J, Kim ES. Randomized, double-blind, placebo-controlled, phase 2 trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs). ASCO Annual Meeting 2017, 2017. e-Pub 2017.
60. Gillison ML, Harrington K, Ferris RL, Guigay J, Blumenschein G, Jr, Fayette J, Colevas AD, Kiyota N, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Saba NF. Nivolumab versus Investigator’s Choice Therapy Among Patients with Human Papillomavirus (HPV)-Associated Squamous Cell Carcinoma of the Head and Neck (SCCHN): Updated Results from CheckMate 141. AHNS Annual Meeting, 2017. e-Pub 2017.
61. Concha-Benavente F, Gillison ML, Blumenschein G Jr, Harrington K, Fayette J, Colevas AD, Licitra L, Kasper S, Even C, Worden FP, Saba NF, Haddad R, Tahara M, Hasegawa Y, C-J Y, Lynch M, Monga M, Geese WJ, Vokes EE, Ferris RL. Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN). ASCO Annual Meeting, 2017. e-Pub 2017.
62. Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Kopit J, Ferris RL. Outcomes in Patients Who Were Platinum-Refractory in the First-Line Recurrent or Metastatic (R/M) Setting and Updated Efficacy and Safety from the Phase 3 CheckMate 141 Study of Nivolumab vs Investigator’s Choice in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN). ASCO 2017, 2017. e-Pub 2017.
63. Ferris RL, Licitra LF, Fayette J, Even C, Blumenschein G Jr, Harrington K, Guigay J, Vokes EE, Saba NF, Haddad RI, Ramkumar S, Russell J, Brossart P, Tahara M, Monga M, Zhu J, Colevas AD, Gillison ML. Nivolumab (Nivo) vs Investigator’s Choice (IC) in Patients With Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN): Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. ASCO Annual Meeting 2017, 2017. e-Pub 2017.
64. Elhammali A, Colbert L, Komaki R, Lee JJ, Gomez DR, O’Reilly MS, Fossella FV, Blumenschein GR Jr, Heymach JV, Allen PK, Hahn SM, Cox JD, Lu CS, Mohan R, Liao Z. Diffusion Capacity of the Lungs following Passive-Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer. ASTRO Conference 2017, 2017. e-Pub 2017.
65. Gillison ML, Blumenschein GR Jr, Fayette J, Guigay J, Colevas AD, Licitra LF, Harrington K, Kasper S, Vokes EE, Even C, Worden FP, Saba NF, Docampo LCI, Haddad RI, Rordorf T, Kiyota N, Tahara M, Lynch MJ, Kopit J, Ferris RL. Nivolumab (Nivo) vs Investigator’s Choice (IC) for Platinum-Refractory (PR) Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN; Checkmate 141): Outcomes in First-line (1L) R/M Patients and Updated Safety and Efficacy. ASCO Annual Meeting 2017, 2017. e-Pub 2017.
66. Jr BG, Chandler J, Garon EB, Waterhouse D, Goldman JW, Gunuganti VK, Boccia R, Spigel D, others. PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC: Topic: Medical Oncology. Journal of Thoracic Oncology 11(11):S307, 2016. e-Pub 2016.
67. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med, 2016. e-Pub 2016. PMID: 27718784.
68. Blumenschein G Jr. CA209-141: Nivolumab vs Investigator's choice (IC) for recurrent or metastatic (R/M) head 7 neck squamous cell carcinoma (HNSCC): Checkmate -141 Session: Immuno-oncology Clinical Trials II. AACR, 2016. e-Pub 2016.
69. Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget, 2016. e-Pub 2016. PMID: 26933802.
70. Hassan R, Bendell JC, Blumenschein G, Kindler HL, Moore KN, Santin AD, Seward SM, Nemunaitis J, Rajagopalan P, Walter A, Sarapa N. Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine in patients with metastatic mesothelioma. J Clin Oncol, ASCO Annual Meeting, 2016. e-Pub 2016.
71. Liao ZX, Lee JJ, Komaki R, Gomez DR, O'Reilly M, Allen P, Fossella FV, Heymach J, Blumenschein GR, Choi NC, Delaney T, Hahn SM, Lu C, Cox JD, Mohan R. Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer. 2016 ASCO Annual Meeting, 2016. e-Pub 2016.
72. Munster PN, Mahipal A, Nemunaitis JJ, Mita MM, Paz-Ares LG, Massard C, Mikkelsen T, Cruz C, Rathkopf DE, Blumenschein GR, Hidalgo M, Smith DC, Eichhorst B, Cloughesy TF, Garrick B, Trowe T, Filvaroff E, Hege K, Bendell JC. Phase I trial of a dual TOR kinase and DNA-PK inhibitor (CC-115) in advanced solid and hematologic cancers. ASCO Annual Meeting, 2016. e-Pub 2016.
73. Ferris RL, Blumenschein GR, Fayette J, Guigay J, Colevas AD, Licitra LF, Harrington KJ, Kasper S, Vokes EE, Even C, Worden FP, Haddad RI, Kiyota N, Tahara M, Monga M, Lynch MJ, Geese WJ, Kopit J, Shaw JW, Gillison ML. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. ASCO Annual Meeting, 2016. e-Pub 2016.
74. Stinchcombe T, Zhang YJ, Vokes EE, Schiller JH, Bradley JD, Curran WJ, Movsas B, Schild SE, Clamon GH, Govindan R, Blumenschein GR, Socinski MA, Ready N, Akerley WL, Cohen HJ, Pang H, Wang XF. A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in u.s. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts). ASCO Annual Meeting, 2016. e-Pub 2016.
75. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Camidge DR, Doebele RC, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Komaki R, Louie AV, Palma DA, Tsao AS, William WN, Zhang J, Swisher S, Heymach J. Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study. ASCO Annual Meeting, 2016. e-Pub 2016.
76. Horn L, Wakelee HA, Reckamp KL, Blumenschein GR, Infante JR, Carter CA, Waqar SN, Neal JW, Gockerman JP, Harrow K, Dukart G, Liang C, Gibbons JJ, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM. Plasma genotyping of patients enrolled on the expansion phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2016. e-Pub 2016.
77. Hassan R, Jennens R, Van Meerbeeck JP, Nemunaitis JJ, Blumenschein GR, Fennell DA, Kindler HL, Novello S, Elbi C, Walter A, Serpico D, Siegel JM, Childs BH. A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum/pemetrexed-based chemotherapy (NCT02610140). ASCO Annual Meeting, 2016. e-Pub 2016.
78. Tran HT, Elamin Y, Simon GR, Blumenschein GR, Tsao AS, Papadimitrakopoulou, V, Gibbons DL, Fossella FV, Lanman RB, Banks KC, Byers LA, Zhang J, Heymach J. Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC). ASCO Annual Meeting, 2016. e-Pub 2016.
79. Bauer TM, Chae YK, Patel S, D'Angelo SP, Blumenschein G, Norton J, Pound C, Lanasa MC, Curti BD. A phase I Study of MED16383, an OX40 agonist, in adult patients with select advanced solid tumors. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
80. Lin SH, Mok I, Leos D, Pasia MG, Thall PF, Lin HY, Welliver MX, Villalona-Calero MA, Yao JC, Meric-Berstam F, Komaki R, Chen HX, Blumenschein G. NCI 9448: Phase I study of trametinib in combination with chemoradiation for KRAS-mutant non-small cell lung cancer. Journal of Clinical Oncology (ASCO) 33(15), 2015. e-Pub 2015.
81. Massarelli E, Haddad RI, Lee JJ, Lin HY, Garden AS, Blumenschein G, William WN, Tishler RB, Glisson BS, Gold KA, Johnson FM, Rabinowits G, Ginsberg LE, Williams MD, Myers J, Kies MS, Papadimitrakopoulou V. Weekly paclitaxel, carboplatin, cetuximab (PCC), and cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF), followed by risk-based local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma (LAHNSCC). Journal of Clinical Oncology (ASCO) 33(15), 2015. e-Pub 2015.
82. Bauer TM, McCleod M, Chandler JC, Blumenschein G, Schwartzberg LS, Burris H, Waterhouse D, Jotte RM, Hussein M, Spigel DR, Thompson DS, Li XM, Reynolds CH. An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) who progressed after receiving 1 or more prior systemic regimes. Journal of Clinical Oncology 33(15), 2015. e-Pub 2015.
83. Balmanoukian AS, Rizvi NA, Garon EB, Patnaik A, Gandhi L, Leighl NB, Goldman JW, Eder JP, Johnson EA, Blumenschein GR, Gubens MA, Papadopoulos KP, Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dollled-Filhard M, Hanson ME, Hui R. Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). International Journal Of Radiation Oncology Biology Physics 90:S1-S2, 2014. e-Pub 2014.
84. Garon E, Gandhi L, Rizvi N, Hui R, Balmanoukian A, Patnaik A, Eder J, Blumenschein G, Aggarwal C, Soria J, Ahn M, Gubens M, Ramalingham S, Johnson E, Arkenau H, Lubiniecki G, Zhang J, Rutledge R, Emancipator K, Leighl N. Antitumor Activity of Pembrolizumab (Pembro; MK-3475) and Correlation With Programmed Death Ligand 1 (PD-L1) Expression in a Pooled Analysis of Patients (pts) With Advanced Non–Small Cell Lung Carcinoma (NSCLC). ESMO 2014, 2014. e-Pub 2014.
85. Munster P, Elkabets M, Gilbert J, Razak A, Ahn M, Yen C, Lee S, Wang H, Van Herpen C, Lim W, Demanse D, Pal R, Huang A, Sheng Q, Lambertini C, Peters M, Coughlin C, Scaltriti M, Baselga J, Blumenschein G. Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell cancer of the head and neck (SCCHN). AACR PI3K Special Congress, 2014. e-Pub 2014.
86. Weidhaas J, Kim E, Herbst R, Yu J, Slack F, Blumenschein G, Tsao A, Wistuba I, Lee J, Papadimitrakopoulou V, Hong W, Heymach J, Tran H. The KRAS-variant and treatment response in BATTLE-1. J Clin Oncol (ASCO), 2014. e-Pub 2014.
87. Garon E, Leighl N, Rizvi N, Blumenschein G, Balmanoukian A, Eder J, Goldman J, Hui R, Soria J, Gangadhar T, Sun J, Patnaik A, Gubens M, Lubiniecki G, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Hanson M, Gandhi L. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO), 2014. e-Pub 2014.
88. Rizvi N, Garon E, Patnaik A, Gandhi L, Leighl N, Balmanoukian A, Goldman J, Eder J, Johnson E, Blumenschein G, Gubens M, Papadopoulos K, Lubiniecki G, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Hanson M, Hui R. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol (ASCO), 2014. e-Pub 2014.
89. Hui R, Garon EB, Leighl NB, Rizvi NA, Blumenschein Jr GR, Balmanoukian AS, Eder JP, Goldman JW, J-C S, Gangadhar TC, J-M S, Patnaik A, Gubens MA, Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Gandhi L. Safety and clinical activity of pembrolizumab (MK-3475) in patients with previously treated NSCLC. 2014 ALCC Annual Meeting, 2014. e-Pub 2014.
90. Hui R, Garon EB, Leighl NB, Rizvi NA, Blumenschein Jr GR, Balmanoukian AS, Eder JP, Goldman JW, J-C S, Gangadhar TC, J-M S, Patnaik A, Gubens MA, Lubiniecki GM, Zhang J, Niewood M, Emancipator K, Dolled-Filhart M, Gandhi L. Safety and clinical activity of pembrolizumab (MK-3475) in patients with previously treated NSCLC. 2014 CMSTO, 2014. e-Pub 2014.
91. Horn L, Infante J, Blumenschein G, Wakelee H, Arkenau H, Dukart G, Liang C, Harrow K, Gibbons J, Lovly C, Pao W. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol (ASCO), 2014. e-Pub 2014.
92. Massarelli E, Haddad R, Lee J, Garden A, Blumenschein G, William W, Tishler R, Glisson B, Gold K, Johnson F, Ginsberg L, Williams M, Myers J, Kies M, Papadimitrakopoulou V. Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma. J Clin Oncol (ASCO), 2014. e-Pub 2014.
93. Ramanathan R, Von Hoff D, Eskens F, Blumenschein G, Richards D, Renshaw F, Rajagopalan P, Kelly A, Pena C, Mross K. A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer. J Clin Oncol (ASCO), 2014. e-Pub 2014.
94. Tran H, Legendre B, Kim E, Blumenschein G, Tsao A, Herbst R, Wistuba I, Lewis M, Richardson K, Hong W, Heymach J. The use of improved and complete enrichment co-amplification at lower denaturation temperature (ICE COLD-PCR) method for the detection of EGFR and KRAS mutations from cell-free plasma DNA of non-small cell lung cancer (NSCLC) patients. J Clin Oncol (ASCO), 2014. e-Pub 2014.
95. Blumenschein Jr GR, Smith EF, Planchard D, Kim DW, Cadranel J, DePas T, Dunphy F, Udud K, Ahn MJ, Hanna NH, Kim JH, Maziere J, Kim SW, Baas P, Rappold E, Redhu S, Bellew KM, Streit MRW, Wu FS, Janne PA. MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non-small cell lung cancer (NSCLC). J Clin Oncol(31), 2013. e-Pub 2013.
96. Gandara DR, Hiret S, Blumenschein Jr GR, Barlesi F, Delord JP, Madelaine J, Infante JR, Reckamp KL, Primo L, Audebert C, Cho BC, Park K, Braiteh FS, Jotte RM, Wu Y, Schramek DJ, Piepszak AM, Gardner OS, Reddy VG, Peddareddigari NB. Oral MEK1/Mek2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. J Clin Oncol(31), 2013. e-Pub 2013.
97. Massarelli E, Ginsberg LE, LIn H, Tran H, Lee JJ, Williams MD, Blumenschein JR GR, Lu C, Kies M, Papadimitrakopoulou V. Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. J Clin Oncol(31), 2013. e-Pub 2013.
98. Parinyanitikul N, Blumenschein Jr GR, Wu Y, Lei X, Chavez-MacGregor M, Smart ML, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple-receptor negative breast cancer. J Clin Oncol 31, 2013. e-Pub 2013.
99. Apostolia MT, Said R, Falchook GS, Janku F, Nain A, Zinner R, Blumenschein Jr GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Ye Y, Hess KR, Palmer GA, Wolff RA, Kurzrock R. Outcomes of patients with advanced cancer and KRAS mutation in phase 1 clinical trials. J Clin Oncol(31), 2013. e-Pub 2013.
100. Tsao AS, Liu S, Lee JJ, Alden CM, Jr BG, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. Journal of Thoracic Oncology 8(5):658-661, 2013. e-Pub 2013.
101. Bendell J, Blumenschein, Jr, GR, Zinner R, Hong D, Jones S, Infante J, Burris H, Rajagopalan P, Kornacker M, Henderson D, Kelly A, Hassan R. First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. AACR Annual Meeting, Clinical Trials Symposium, April 9, 2013, Washington, DC, 2013. e-Pub 2013.
102. Juric D, Dienstmann R, Cervantes A, Hildalgo M, Messersmith W, Jr B, GR, Baselga J, Tabernero J, Roda D, Calles A, Jimeno A, Amler L, Stern H, Sanabria S, Penuel E, Pirzkall A. Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients enrolled in a Phase I study of MEHD7945A (MEHD, a first-in-class HER3/EGFR dual action antibody, inpatients with locally advanced metastatic epithelial tumors. AACR Annual Meeting Poster Session; April 9, 2013, Washington, DC, 2013. e-Pub 2013.
103. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research 19(1):279-290, 2013. e-Pub 2013.
104. Blumenschein Jr GR, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, others A. Sunitinib Plus Erlotinib for the Treatment of Advanced/Metastatic Non–Small-Cell Lung Cancer: A Lead-In Study. Journal of Thoracic Oncology 7(9):1406-1416, 2012. e-Pub 2012.
105. Komaki RU, Allen PK, Wei X, Blumenschein GR, Wistuba II, Lee J, Welsh J, O'Reilly MS, Tang XM, Hong WK. The Phase II Trial of Erotinib and Radiotherapy Folling Chemoradiotherapy for Patients with Stage III Non-Small Cell Lung Cancer Has Shown a Favorable Response Profile. International journal of radiation oncology, biology, physics, 2012. e-Pub 2012.
106. Juric D, Dienstmann R, Messersmith W, Cervantes A, Blumenschein Jr G, Baselga J, Tabernero J, Jimeno A, Calles A, Roda D, Xin Y, Kapp AV, Chandler GS, Pirzkall A. A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr CT-08, 2012. e-Pub 2012.
107. Saintigny P, Blumenschein Jr GR, Diao L, Wang J, Coombes K, Liu S, Kim E, Tsao A, Herbst R, Alden C, Lee JJ, Tang X, Stewart D, Kies M, Fossella F, Tran H, Mao L, Hicks M, Erasmus J, Gupta S, Girard L, Peyton M, Davis S, Lippman S, Hong WK, Minna J, Wistuba I, Heymach J. Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small lung cancer (NSCLC). In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr 4819, 2012. e-Pub 2012.
108. Blumenschein GR, Glisson BS, Lu C, Sabichi AL, Ginsberg LE, Bartos CI, Feng L, Tran HT, El-Naggar AK, Lippman SM, Kies MS. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 30(5592), 2012. e-Pub 2012.
109. Becerra C, Infante JR, Garbo LE, Gordon MS, Smith DA, Braiteh FS, Gandara DR, Jotte RM, Reckamp KL, Janku F, Burris HA, Bellew KM, Gardner OS, Liu L, Cox DS, Peddareddigari VG, Blumenschein GR. A five-arm, open-label, phase I/lb study to assess safety and tolerability of the oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with chemotherapy or erlotinib in patients with advanced solid tumors. J Clin Oncol 30(suppl; abstr 3023), 2012. e-Pub 2012.
110. Cervantes-Ruiperez A, Juric D, Hidalgo M, Messersmith WA, Blumenschein GR, Baselga J, Perez DR, Dienstmann R, Calles A, Jimeno A, Sanabria S, Littman C, Amler LC, Pirzkall A, Tabernero A. A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts. J Clin Oncol 30(suppl; abstr 2568), 2012. e-Pub 2012.
111. Hidalgo M, Calles A, Juric D, Dienstmann R, Perez DR, Messersmith WA, Blumenschein GR, Baselga J, Tabernero J, Cervantes-Ruiperez A, Jimeno A, Jin D, Bai S, Gurevich P, Nijem I, Holden SN, Davis JD, Halpern W, Pirzkall A, Xin Y. Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors. J Clin Oncol 30(suppl; abstr 2567), 2012. e-Pub 2012.
112. Saintigny P, Diao L, Wang J, Girard L, Lin SH, Coombes KR, Liu S, Lee JJ, Weinstein JN, Xie Y, Fan YH, Tang XM, Kim ES, Herbst RS, Tsao A, Blumenschein GR, Mao L, Lippman SM, Minna JD, Hong WK, Wistuba II, Heymach JV. A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS. Proc. of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL, 2011. e-Pub 2011.
113. Ihle NT, Herbst RS, Kim ES, Wistuba II, Lee JJ, Blumenschein, Jr GR, Tsao AS, Chen L, Zhang S, Alden CM, Tang X, Liu S, Stewart DJ, Papadimitrakopoulou V, Heymach JV, Tran HT, Hicks ME, Erasmus JJ, Gupta S, Minna JD, Larsen J, Lippman SM, Hong WK, Powis G. Specific forms of mutant KRAS predict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer. Proc. of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, 2011. e-Pub 2011.
114. Heymach JV, Saintigny P, Kim ES, Byers LA, Lee JJ, Coombes K, Diao L, Wang J, Tran HT, Fan YH, Tsao A, Blumenschein Jr GR, Papadimitrakopoulou VA, Tang X, Story M, Xie Y, Girard L, Weinstein J, Mao L, Minna JD, Herbst RS, Lippman SM, Hong WK, Wistuba II. Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination). Proc. of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL, 2011. e-Pub 2011.
115. Vashishtha A, Patel PH, Yu W, Bothos JG, Simpson J, Maneatis T, Doessegger L, Peterson AC, Clement-Duchene C, Robinet G, Krzakowski M, Blumenschein GR, Goldschmidt JH, Daniel DB, Spigel DR. Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC, 2011. e-Pub 2011.
116. Johnson BE, Kris MG, Kwiatkowskii D, Iafrates IJ, Wistuba II, Shyr Y, Engelman J, Khuri FR, Dubinett S, Pao W, Rudin C, Schiller J, Haura EB, Blumenschein G, Simon G, Giaccone G, Koehler E, Kugler K, Minna JD, Bunn P. Clinical characteristics of planned 1000 patients with Adenocarcinoma of Lung (ACL) undergoing genomic characterization in the us Lung Cancer Mutation Consortium (LCMC). Proc. of the 14th World Conference on Lung Cancer, Amsterdam, Netherlands, 2011. e-Pub 2011.
117. Spigel D, Ervin T, Ramlau R, Daniel DB, Goldschmidt J, Blumenschein G, Krzakowski M, Robinet G, Clement-Duchene C, Barlesi F, Govindan R, Patel T, Orlov S, Wertheim MS, Zha J, Pandita A, Yu W, Yauch R, Patel P, Peterson AC. Final efficacy results from a randomized phase II study (OAM4558G) Evaluating Metmab or placebo in combination with erlotinib in advanced NSCLC. Proc. of the 14th World Conference on Lung Cancer, Amsterdam, Netherlands, 2011. e-Pub 2011.
118. Vashishtha A, Patel PH, Yu W, Bothos JG, Simpson J, Maneatis T, Doessegger L, Peterson AC, Clement-Duchene C, Robinet G, Krzakowski M, Blumenschein GR, Goldschmidt JH, Daniel DB. Safety date and patterns of progression in MET diagnostic subgroups in OAM4558g; A phase II trials evaluating Met-MAb in combination with erlotinib in advanced NSCLC. Journal of Clinical Oncology 29, 2011. e-Pub 2011.
119. Blumenschein GR, Molina JR, Lathia CD, Ong TJ, Roth D, Rajagopalan P, Fossella FV, Kies MS, Marks RS, Adjei AA, Sundaresan PR. Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 29, 2011. e-Pub 2011.
120. Komaki R, Blumenschein GR, Wistuba II, Lee JJ, Allen P, Wei X, Welsh J, O'Reilly M, Herbst RS, Tang X, Meyn R, Liu D, Hong WK. Phase II trial of erlotinib and radiotherapy following chemoradiotherapy for patients with stage III non-small cell lung cancer. Journal of Clinical Oncology 29, 2011. e-Pub 2011.
121. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, RobinetS G, Clement-Duchene C, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Zha J, Pandita A, Yu W, Yauch RL, Patel PH, Peterson AC. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. Proc. of the 14th World Conference on Lung Cancer, Amsterdam, Netherlands 29, 2011. e-Pub 2011.
122. Kies MS, Blumenschein Jr GR, Christensen O, Lin T, Tolcher AW. Phase I study of regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, administered continuously in patients (pts) with advanced refractory non-small cell lung cancer (NSCLC). J Clin Oncol 28(15s), 2010. e-Pub 2010.
123. Shimizu T, Tolcher AW, Patnaik A, Papadopoulos K, Christensen O, Lin T, Blumenschein Jr GR. Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors. J Clin Oncol 28(15s), 2010. e-Pub 2010.
124. Sabichi AL, Kies MS, Glisson BS, Lu C, Ginsberg LE, Bartos CI, Feng L, Tran HT, Lippman SM, Blumenschein Jr GR. A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol 28(15s), 2010. e-Pub 2010.
125. Herbst RS, Blumenschein Jr GR, Kim ES, Lee J, Tsao AS, Alden CM, s L, Stewart DJ, Wistuba II, Hong WK. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. J Clin Oncol 28(15s), 2010. e-Pub 2010.
126. Blumenschein GR, Kabbinavar FF, Menon H, Mok T, Stephenson J, Beck JT, Lakshmaiah K, Kracht K, Sikorski RS, Schwartzberg LS. Randomized, open-label phase II study of motesanib or bevacizumab in combination with paclitaxel and carboplatin (P/C) for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 28(15s), 2010. e-Pub 2010.
127. Bass MB, Davis MT, Kivman L, Khoo H, Notari K, Blumenschein Jr GR, Mackey JR, Sherman SI, Hei Y, Patterson SD. Placental growth factor as a marker of therapeutic response to treatment with motesanib in patients with progressive advanced thyroid cancer, advanced nonsquamous non-small cell lung cancer, and locally recurrent or advanced metastatic breast cancer. J Clin Oncol 28(15s), 2010. e-Pub 2010.
128. Kim ES, Herbst RS, Lee JJ, Blumenschein Jr GR, Tsao A, Alden CM, Tang X, Liu S, Stewart DJ, Heymach JV, Tran HT, Hicks ME, Erasmus Jr J, Gupta S, Powis G, Lippman SM, Wistuba II, Hong WK. The BATTLE trial (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination): personalizing therapy for lung cancer. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; 2010. Abstract nr LB-1, 2010. e-Pub 2010.
129. Tsao AS, Liu D, Lee JJ, Heymach J, Pisters K, Brewer H, Hong WK, Blumenschein GR. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemo-naive patients with unresectable malignant pleural mesothelioma. IASLC 13th World Conference on Lung Cancer, 2009. e-Pub 2009.
130. Tam A, Kim ES, Herbst R, Wistuba II, Lee JJ, Alden C, Tsao A, Blumenschein GR, Erasmus J, Hicks ME, Hong WK, Gupta S. Personalized lung cancer therapy: Safety and adequacy of image-guided small-caliber core needle biopsy for evaluation of multiple molecular biomarkers. IASLC 13th World Lung Conference, San Francisco, CA, 2009. e-Pub 2009.
131. Kim ES, Herbst RS, Lee JJ, Blumenschein GR, Tsao A, Tang X, Wistuba II, Alden C, Gupta S, Stewart DJ, Lippman SM, Hong WK. A phase II study of biomarker-directed treatment for advanced non-small cell lung cancer (NSCLC): The BATTLE (Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination) clinical trial program. IASLC 13th World Lung Conference, San Francisco, CA, 2009. e-Pub 2009.
132. Melara R, Sutjandra L, Bruenner B, Wake C, Blumenschein GR Jr, Schwartzberg L, Sikorski R, Y-J H, J-F L, Y-N S. Pharmacokinetics (PK) of Motesanib in a Randomized, Open-label, Phase 2 Study of Motesanib or Bevacizumab in Combination With Paclitaxel and Carboplatin (P/C) for Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC): Analysis of Population PK Model Predictions. IASLC 13th World Conference on Lung Cancer, San Francisco, CA, 2009. e-Pub 2009.
133. Bass MB, Hamic K, Khoo M, Kivman L, Davis M, Blumenschein GR, Schwartzberg L, Sikorski R, Y-J H. Treatment With Motesanib or Bevacizumab Results in Differential Changes in Levels of Several Serum Proteins Including Placental Growth Factor (PlGF) and Soluble Kinase Domain Receptor (sKDR): Results From a Randomized, Open-label, Phase 2 Study of Motesa. IASLC 13th World Lung Conference, San Francisco, CA, 2009. e-Pub 2009.
134. Tsao AS, Gil J, Rice D, Swisher S, Lee JJ, Lippman SM, Pisters K, Blumenschein GR Jr, Hong WK, Mehran R. Phase I trial of neoadjuvant dasatinib in patients with resectable malignant pleural mesothelioma. IASLC 13th World Conference on Lung Cancer, San Francisco, CA, 2009. e-Pub 2009.
135. Papadimitrakopoulou V, Frank SJ, Blumenschein GR, Chen C, Kane M, Cohen EE, Langmuir P, Krebs AD, Lippman SM, Raben D. Phase I evaluation of vandetanib with radiation therapy (RT) + cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC). 2009 ASCO Annual Meeting. J Clin Oncol 27(15s), 2009. e-Pub 2009.
136. Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte N, Kim ST, Chao R, Wilding G. Sunitinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors: Updated phase I study results. 2009 ASCO Annual Meeting. J Clin Oncol 27, 2009. e-Pub 2009.
137. Blumenschein GR, Paulus R, Curran W, Robert F, Fossella F, Werner-Wasik M, Doescher P, Choy H, Komaki R. A Phase II Study of Cetuximab (C225) in Combination with Chemoradiation (CRT) in Patients (PTS) with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC): A Report of the 2 Year and Median Survival (MS) for the RTOG 0324 Trial. Journal of Thoracic Oncology. 3(11):S263-S305, 2008. e-Pub 2008.
138. Govindan R, Blumenschein GR, Groen HJM, Szczesna A, Strausz J, Montesinos J, Tye L, Chao RC, Scagliotti GV. Sunitinib (SU) Plus Erlotinib (E) for Metastatic Non-small Cell Lung Cancer (NSCLC): A Novel VEGFR-EGFR Combination Treatment Strategy. Journal of Thoracic Oncology. 3(11):S263-S305, 2008. e-Pub 2008.
139. Heath EI, Blumenschein GR, Cohen RB, LoRusso PM, LoConte N, Kim ST, Chao R, Wilding G. Safety and Efficacy of Sunitinib in Combination with Carboplatin (C) Plus Paclitaxel (Pac) in Patients (Pts) with Advanced Solid Tumors (STs): a Phase I Study. Journal of Thoracic Oncology. 3(11):S263-S305, 2008. e-Pub 2008.
140. Blumenschein GR. Pharmacokinetics (PK) of Motesanib in a Randomized, Open-label, Phase 2 Study of Motesanib or Bevacizumab in Combination with Paclitaxel and Carboplatin (P/C) for Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC): Analysis of Population PK Model Predictions. IASLC 13th World Lung Conference, San Francisco, CA, 2008. e-Pub 2008.
141. Camacho LH, Moulder SL, LoRusso PM, Blumenschein GR, Bristow PJ, Kurzrock R, Fu S, Schlienger K, Bergstrom DA. First in human phase I study of MK-2461, a small molecule inhibitor of c-Met, for patients with advanced solid tumors. J Clin Oncol 26(15s Part I of II):639s, 2008. e-Pub 2008.
142. Kies MS, Gibson MK, Kim SW, Savvides P, Blumenschein GR, Worden F, Chen H, Grandis JR, Argiris AE. Cetuximab (C) and bevacizumab (B) in patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN): An interim analysis. J Clin Oncol 26, 2008. e-Pub 2008.
143. Papadimitrakopoulou V, Blumenschein, Jr GR, Leighl NB, Bennouna J, Soria JC, Burris III HA, Dimitrejevic S, Kunz T, Di Scala L, Johnson BE. A phase 1/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): Phase I results. J Clin Oncol 26(15s Part I of II), 2008. e-Pub 2008.
144. Olsen CC, Paulus R, Komaki R, Varella-Garcia M, Dziadziuszko R, Curran WJ, Robert F, Choy H, Blumenschein GR, Hirsch FR. RTOG 0324: a phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)--Association between EGFR gene copy number and patients' out-come. J Clin Oncol 26(15S Part I of II):423s, 2008. e-Pub 2008.
145. Blumenschein Jr GR, Paulus R, Curran WJ, Robert F, Fossella FV, Werner-Wasik M, Doescher P, Choy H, Komak R. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 26(15s), 2008. e-Pub 2008.
146. Heath EI, Blumenschein Jr GR, Cohen RB, LoRusso PM, LoConte NK, Kim ST, Chao R, Wilding G. Phase I study of sunitinib in combination with carboplatin (C) plus paclitaxel (P) in patients (pts) with advanced solid tumors (STs). J Clin Oncol 26(15S Part I of II):169s, 2008. e-Pub 2008.
147. Pena C, Gatzemeier U, Lathia C, Fossella F, Reck M, Elting J, Blumenschein GR. Plasma biomarkers in a phase II trial of sorafenib in advanced non-small cell lung cancer. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics-- Oct 22-26, 2007; San Francisco, CA; Abstract No B18, 2007. e-Pub 2007.
148. Blumenschein, G. A lead-in safety study of erlotinib combined with sutinib for the treatment of metastatic non-small cell lung cancer (NSCLC). Poster Session, IASLC 12th World Conference on Lung Cancer, 2007. e-Pub 2007.
149. Blumenschein, G. A Phase II Study of Cetuximab (C225) In Combination with Chemoradation. Oral Presentation, IASLC 12th World Conference on Lung Cancer, Seoul Korea, 2007. e-Pub 2007.
150. Blumenschein G Jr R G, Robert F, Melnyk O, Sutherland KC, Tye L, Wang E, Chao R, Fossella F. Phase II study of erlotinib (E) with or without sunitinib (SU) in the treatment of metastatic non-small cell lung cancer (NSCLC) (oral presentation). ECCO 14 Barcelona 2007 Conference, 2007. e-Pub 2007.
151. Jr BG, Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden C, Herbst RS, Reckamp K. Safety and Pharmacokinectics (PK) of AMG 706 with Carboplatin/Pacitaxel (C/P) and/or Pantumumab for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). Poster Session, IASLC 12th World Conference on Lung Cancer, Seoul, Korea, 2007. e-Pub 2007.
152. Uyeki J, Johnson FM, Feng L, Peeples BO, Blumenschein G, Fossella FV, Karp DD, Pisters KM, Stewart DJ, Glisson BS. Phase II trial of irinotecan plus cisplatin (IP) and etoposide plus cisplatin (EP) given weekly on alternating weeks with granulocyte colony-stimulating factor support in the treatment of extensive-stage small cell lung cancer. 2007 ASCO Annual Meeting, Chicago, IL, 2007. e-Pub 2007.
153. Chen L, Vogelzang NJ, Blumenschein G, Robert F, Pluda JM, Frankel SR, Sharma S. Phase I trial of vorinostat (V) in combination with pemetrexed (Pem) and cisplatin (CDDP) in patients with advanced cancer. 2007 ASCO Annual Meeting, Chicago, IL, 2007. e-Pub 2007.
154. Onn A, Martinez CH, Herbst RS, Riddle JR, Blumenschein GR, Stewart DJ, Marom EM. Clinical implications of tumor cavitation following therapy with angiogenesis inhibitors in non-small cell lung cancer (NSCLC) patients. 2007 ASCO Annual Meeting, Chicago, IL, 2007. e-Pub 2007.
155. Mekhail T, Gettinger S, Blumenschein, G, Axelrod R, Haigentz M, Guarino MJ, Cahill AL, Spigel D, Greco FA. A phase II trial of VNP40101M in patients with relapsed or refractory small cell lung cancer (SCLC) with or without brain metastases. 2007 ASCO Annual Meeting, Chicago, IL, 2007. e-Pub 2007.
156. Blumenschein G, Moughan J, Curran W, Robert F, Fossella F, Werner-Wasik M, Doescher P, Choy H, Komaki R. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC): An interim report of the RTOG 0324 trial. 2007 ASCO Annual Meeting, Chicago, IL, 2007. e-Pub 2007.
157. Smylie M, Blumenschein GR, Dowlati A, Garst J, Shepherd FA, Rigas JR, Hassani H, Berger MS, Zaks T, Ross HJ. A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history. 2007 ASCO Annual Meeting, Chicago, IL, 2007. e-Pub 2007.
158. Morrow PH, Glisson BS, Ginsberg LE, Lippman SM, Kies MS, Blumenschein GR, Ayuste RC, Feng L, Papadimitrakopoulou VA, Kim ES. A phase I dose escalation study of pemetrexed in patients with advanced head and neck squamous cell cancer (HNSCC). 2007 ASCO Annual Meeting, Chicago, IL, 2007. e-Pub 2007.
159. Mekhail T, Gettinger S, Blumenschein G Jr, Axelrod R, Haigentz M, Guarino M, Cahill A, Spigel D, Greco FA. A phase II trial of Cloretazine® (VNP40101M) in patients with relapsed or refractory Small Cell Lung Cancer (SCLC) with or without brain metastases. Poster Session, The 4th International Chicago Symposium on Malignancies of the Chest and Head & Neck, 2006. e-Pub 2006.
160. Blumenschein G Jr, Glisson B S, Burke B, Erasmus J, Zinner R, Kies M. Phase II Trial of Gefitinib in Patients with Incurable Salivary Gland Cancer. Poster Presentation, The 4th International Symposium on Malignancies of the Chest and Head & Neck, 2006. e-Pub 2006.
161. Papadimitrakopoulou V, Blumenschein G, Rollins M, Adjei AA, Dimitrijevic S, Kunz T, Discala L, Johnson BE. A phase I/II study investigating the combination of RAD001(R) (everolimus) and erlotinib (E) as 2nd/3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy. 2006 ASCO Annual Meeting, Atlanta, GA, 2006. e-Pub 2006.
162. Blumenschein G Jr, Sandler A, O'Rourke T, Eschenberg M, Sun Y, Gladish G, Salgia R, Alden C, Herbst RS, Reckamp K. Safety and pharmacokinetics (PK) of AMG 706, panitumumab, and carboplatin/paclitaxel (CP) for the treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). Poster Session, 2006 ASCO Annual Meeting, Atlanta, GA, 2006. e-Pub 2006.
163. Gatzemeier U, Blumenschein G, Fosella F, Simantov R, Elting J, Bigwood D, Cihon F, Reck M. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. 2006 ASCO Annual Meeting, Atlanta, GA, 2006. e-Pub 2006.
164. Glisson BS, Kim ES, Kies MS, Francisco M, Blumenschein GR, Tsao AS, Clayman GL, Duvic M, Weber RS, Lippman SM. Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin. 2006 ASCO Annual Meeting, Atlanta, GA, 2006. e-Pub 2006.
165. Gatzemeier U, Blumenschein G Jr, Jotte R, von Pawel J, Jr MW, Khuri F, Rigas J, Mabry M, Dziewanowska, Negro-Vilar A. A phase III randomized trial of carboplatin/paclitaxel, with or without bexarotene (Targretin®), in chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer (NSCLC). 11th World Conference on Lung Cancer, Barcelona, Spain, 2005. e-Pub 2005.
166. Blumenschein G, Swann S, Curran W, Robert F, Werner-Wasik M, Lee CP, Jafar S, Share R, Choy H, Komaki R. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 trial. 11th World Conference on Lung Cancer, Barcelona, Spain, 2005. e-Pub 2005.
167. Papadimitrakopoulou V, Edelman M, Zinner R, Blumenschein G Jr, Jones S, Willcutt N, Keck J, Brown G, Burris H. Phase 1-2 dose-ranging trial of TLK286 (TELCYTA) and cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC). 11th World Conference on Lung Cancer, Barcelona, Spain, 2005. e-Pub 2005.
168. Blumenschein G, Ludwig C, Thomas G, Tan E, Fanucchi M, Santoro A, Crawford J, Breton J, O’Brien M, Khuri F. A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). 11th World Conference on Lung Cancer, Barcelona, Spain, 2005. e-Pub 2005.
169. Altundag O, Stewart D, Stevens C, Rice D, Ayers G, Blumenschein G, Karp D, Hong W, Fossella F, Zinner R. Some patients (pts) with “wet” IIIB non-small cell lung cancer (NSCLC) may not develop distant metastases: A retrospective study. Poster Session, 11th World Conference on Lung Cancer, Barcelona, Spain, 2005. e-Pub 2005.
170. Liao Z, Komaki R, Milas L, Cehn Y, Kies, M, Chang J, Jeter M, Guerrero T, Blumenschein G, Cox J. A dose escalation clinical trial using thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer (NSCLC). 11th World Conference on Lung Cancer, Barcelona, Spain, 2005. e-Pub 2005.
171. Werner-Wasik M, Swann S, Curran W, Robert F, Komaki R, Lee CP, Jafar S, Share R, Choy H, Blumenschein G. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): an interim overall toxicity report of the RTOG 0324 trial. General Poster Session, 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
172. Wang J, Wei W, Lee JJ, Blumenschein G, Hong WK, Lu C. Second primary tumors (SPTs) in patients (PTS) with non-small cell lung cancer (NSCLC): a retrospective cohort study. General Poster Session, 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
173. Ross HJ, Blumenschein GR, Dowlati A, Aisner J, Rigas JR, Stanislaus M, Leopold LH. Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer. General Poster Session, 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
174. Komaki R, Allen P, Glisson B, Lu C, Fossella F, Liao Z, Jeter M, Stevens C, Chang J, Guerrero T, Blumenschein G. Hyperfractionated/accelerated thoracic radiation therapy (HFXRT) increased survival compared to daily RT (QDRT) for limited small cell lung cancer (LSCLC) with concurrent chemotherapy (ChT). General Poster Session, 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
175. Kies MS, Sturgis E, Sabichi A, Blumenschein G, Glisson B, Garden AS, Burke B, Lewin JS, Barringer D, El-Naggar, AK. Induction chemotherapy followed by surgical resection for young patients with squamous cell carcinoma of the oral tongue (SCC/T). Poster Discussion, 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
176. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M. Poster Discussion, Phase II trial of gefitinib in patients with incurable salivary gland cancer. 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
177. Blumenschein GR, Khuri F, Gatzemeier U, Miller WH, Von Pawel J, Rigas JR, Herbst RS, Dziewanowska Z, Negro-Vilar A, Mabry M. A randomized phase III trial comparing bexarotene/carboplatin/paclitaxel versus carboplatin/paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Oral Presentation, 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
178. Altundag O, Stewart DJ, Stevens C, Rice DC, Ayers GD, Blumenschein GR, Karp DD, Hong WK, Fossella FV, Zinner RG. The risk of distant metastases in patients with non-small cell lung cancer (NSCLC) with cytologically proven malignant pleural effusion, stage IIIB: a retrospective analysis. General Poster Session, 2005 ASCO Annual Meeting, Orlando, Florida, 2005. e-Pub 2005.
179. Liao Z, Komaki R, Milas L, Chen Y, Kies M, Chang J, Jeter M, Guerrero T, Blumenschein G, Cox J. A dose escalation clinical trial using thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Poster Session, 11th World Conference on Lung Cancer, Barcelona, Spain, 2005. e-Pub 2005.
180. Blumenschein G Jr, Gatzemeier U, Fossella F, Burk K, Reck M. A Phase II Multicenter Uncontrolled Trial of Single Agent Sorafenib (BAY 43-9006) in patients with Relapsed or Refractory Advanced Non-small-cell-Lung Carcinoma. 2005 AACR-EORTC Molecular Targets and Cancer Therapeutics, Philadelphia, PA, 2005. e-Pub 2005.
181. Altundag O, Stewart DJ, Stevens C, Rice DC, Ayers GD, Blumenschein GR, Karp DD, Hong WK, Fossella FV, Zinner RG. The risk of distant metastases in patients with non-small cell lung cancer (NSCLC) with cytologically proven malignant pleural effusion, stage IIIB: a retrospective analysis. 2005 ASCO Annual Meeting, 2005. e-Pub 2005.
182. Herbst RS, Johnson D, Blumenschein G, Henderson T, Lee J, Truong M, Mass R, Kim E, Garcia B, Sandler AB. Erlotinib in combination with vbevacizumab for patients with recurrent non-small cell lung cancer: A phase I/II trial. Poster Discussion, 29th ESMO Congress 2004, Vienna, Austria, 2004. e-Pub 2004.
183. Papadimitrakopoulou V, Boasberg P, Figlin R, Zinner R, Blumenschein G, King L, Truong M, Patel K, Brown GL, Hanna N. Phase 1-2a dose ranging study of TLK286 (a novel glutathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer. Poster Presentation, ASCO 40th Annual Meeting, New Orleans, Louisiana, 2004. e-Pub 2004.
184. Tran HT, Zinner R, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum B, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial of paclitaxel (pac) and carboplatin (C) combined with erlotinib (E) or placebo in patients with advanced non-small cell lung cancer. Poster Presentation, ASCO 40th Annual Meeting, New Orleans, Louisiana, 2004. e-Pub 2004.
185. Sandler AB, Blumenschein GR, Henderson T, Lee J, Truong M, Kim E, Mass B, Garcia B, Johnson DH, Herbst RS. Phase I/II trial evaluating the anti-VEGF Mab bevacizumab in combination with erlotinib, a HER 1/EGFR-TK inhibitor, for patients with recurrent non-small cell lung cancer. ASCO 40th Annual Meeting, New Orleans, Louisiana, 2004. e-Pub 2004.
186. Koshy S, Herbst RS, Obasaju CK, Fossella F, Papadimitrakopoulou V, Pisters KM, Blumenschein G, Peeples BO, Hong WK, Zinner RG. A phase II trial of pemetrexed plus carboplatin in patients with advanced non-small-cell lung cancer. ASCO 40th Annual Meeting, New Orleans, Louisiana, 2004. e-Pub 2004.
187. Blumenschein G, Lu C, Kies M, Glisson B, Papadimitrakopoulou V, Zinner R, Kim E, Gillenwater A, Chiao J, Hong W. Phase II clinical trial of suberoylanilide hydroxamic acid (SAHA) in patients (pts) with recurrent and/or metastatic head and neck cancer. Poster Presentation, ASCO 40th Annual Meeting, New Orleans, Louisiana, 2004. e-Pub 2004.
188. Koshy S, Herbst RS, Obasaju CK, Fossella F, Papadimitrakopoulou V, Pisters KM, Blumenschein G, Peeples BO, Hong WK, Zinner RG. A phase II trial of pemetrexed plus carboplatin in patients with advanced non-small-cell lung cancer. 2004 ASCO 40th Annual Meeting, New Orleans, Louisiana, 2004. e-Pub 2004.
189. Papadimitrakopoulou V, Figlin R, Garland L, Blumenschein G, Fossella F, Von Hoff DD, King L, Brown GL, Mascavage J, Henner WD. Phase 2 study of TLK286 (GST P1-1 activated glutathione analog) administered weekly in patients with non-small cell lung cancer (NSCLC) who failed prior platinum-based regimens. Am Soc Clin Onc, 2004. e-Pub 2004.
190. Robert F, Blumenschein, G, Dicke K, Tseng J, Saleh MN, Needle M. A phase Ib/IIa study of anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, in combination with gemcitabine/Carboplatin in patients with advanced non-small cell lung cancer. Am Soc Clin Onc 22:643, 2003. e-Pub 2003.
191. Papadimitrakopoulou V, Zinner R, Blumenschein G, King L, Boasberg P, Keck J, Mascavage J, Jameson A, Patel K, Parra R, Brown GL, Hanna N. Phase 1-2a dose ranging study of TLK286 (Telcyta TM, a novel gluthathione analog) in combination with docetaxel in platinum-resistant non-small cell lung cancer. AACR-NCI-EORTC International Conference, 2003. e-Pub 2003.
192. Blumenschein GR. A Phase I Study of TNP-470 Continuous Infusion Alone or in a Combination Paclitaxel and Carboplatin in Adult Patients with Non-small Cell Lung Cancer (NSCLC) and Other Solid Tumors. 14th EORTC – NCI – AACR Symposium on Molecular Targets and Cancer Therapeutics, 2002. e-Pub 2002.
193. Komaki R, Lee JS, Milas L, Kaplan B, Allen P, Liao Z, Stevens CW, Fossella FV, Zinner RG, Papadimitrakopoulou V, Khuri F, Herbst RD, Kies MS, Blumenschein GR, Glisson B, Hong WK, Morice R, Cox JD. Phase III Trial of Amifostine With Chemoradiation for Inoperable Non-Small Cell Lung Cancer (NSCLC): Does Amifostine Protect Cancer Cells?. Am Soc Therapeut Rad Oncol, 2002. e-Pub 2002.
194. Johnson FM, Kurie JM, Pisters KM, Fossella FV, Peeples BO, Papadimitrakopoulou V, Blumenschein GR, Kies MS, Komaki R, Glisson BS. Phase I trial of weekly etoposide (E), cisplatin (P), and irinotecan (I) with G-CSF in patients with small cell lung cancer. Proc Am Soc Clin Oncol 21:312q, 2002. e-Pub 2002.
195. Blumenschein GR. A Phase I Study of Continuous Infusion of TNP-470 Alone or in Combination with Paclitaxel and Carboplatin in Adult Patients with Solid Tumors. AACR NCI-EORTC International Conference, 2001. e-Pub 2001.
196. Blumenschein GR, Khuri FR, Fossella FV, Lee JS, Shin DM, Liu D, Lu C, Munden RF, Lu R, Lee JJ, Hong WK, Herbst RS. Final report of the M. D. Anderson Phase II Study of Combination Weekly Gemcitabine and Vinorelbine in Patients with Untreated or Previously Treated Non-Small Cell Lung Cancer. Proc Am Soc Clin Oncol 20: 2001 (abstr 1371), 2001. e-Pub 2001.
197. McKean M, Frentzas S, Rasco D, Powderly J, Welckhardt A, Hion A, de Souza P, Blumenschein G, Ganju V, Hu-Lieskovan S, Kichenadasse G, Oakman C, Lakhani N, Wyant T, Tang J, Richards L, Knickerbocker A, Amit I, Ofran Y, Vasselli J. AU-007, a human monoclonal antibody (mAb) that binds to IL-2 and inhibits CD25 binding, plus lowdose aldesleukin, in advanced solid tumors: Phase 2 update. AACR Annual Meeting 2025.
198. Altan M, Aminu M, Vokes NL, Saad MB, Li H, Hong L, Mohamed MS, Boom J, Chen P, Gandhi S, Swisher S, Antonoff MB, Pozadzides JV, Blumenschein GR, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao AS, Tu J, Lee JJ, Zhang J, Heymach JV, Wu J. NSCLC Tumor Volumetric Analysis to Correlate Disease Burden with Response to Dual Immune Checkpoint Blockade in Metastatic. AACR Annual Meeting 2023.
199. Altan M, Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Antonoff M, Le X, Tu JC, Pek M, Poh J, Ngeow KC, Tsao AS, Cascone T, Negrao MV, Blumenschein GR, Heymach J, Elamin YY. Longitudinal Tracking of ALK-positive Lung Cancer from Plasma using Circulating-tumor RNA and Circulating-tumor DNA in the BRIGHTSTAR Clinical Trial. 2023 ASCO Annual Meeting.
200. Altan M, Lin S, Liu Y, Tidwell BS, Thall PF, Chun S, Chang JY, Liao Z, Lee Z, Marcondes M, Tagliaferri M, Blumenschein GR, Heymach JV, Tu J. Restoring Lymphocytes Using NKTR-255 after Chemoradiotherapy in Solid Tumors (RESCUE). IASLC Annual Meeting 2023.
201. Altan M, Elamin Y, Gandhi S, Saad M, Rehmani S, Antonoff MB, Gibbons DL, Le X, Negrao M, Lam V, Tu J, Gay C, Byers L, Cascone T, Blumenschein GR, Chang J, Vaporciyan A, Liao Z, Swisher S, Yin J, Park K, Zhang P, Wu J, Heymach J. BRIGHTSTAR Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC. IASLC Annual Meeting 2023.
202. Lin SH, Chen YS, Gupta P, Kahanek M, Tidwell BS, Hwang H, Thall PF, Chun SG, Chang JY, Liao Z, Lee Z, Marcondes M, Tagliaferri M, Zalevsky J, Blumenschein GR, Tu J, Heymach JV, Altan M. Restoring lymphocytes Using NKTR-255 after chemoradiotherapy in solid tumors (RESCUE): Preplanned Interim Safety and Efficacy Analysis. 39th SITC Annual Meeting 2024.
203. Heist R, Shum E, Garcia E, Itchins M, Gao B, Han JY, Blumenschein GR, Benafif S, Alexander M, Joshi R, Lee JH, Coupe N, Girard N, Fiske B, Traianova M, Downing WT, Nguyen T, Wu TH, Gallant G, Kim HR. MYTX-011, a cMET-targeting Antibody-Drug conjugate (ADC), in Patients with Previously Treated, Advanced NSCLC: Updated Dose Escalation Results in the Phase 1 KisMET-01 Study. 2025 ASCO Annual Meeting.
204. Amaria RN, Kopetz S, Morelli MP, Blumenschein GR, Altan M, Sanber K, Jazaeri AA, Davies MA, Diab A, Glitza IC, McQuade JL, Ikeguchi A, Tawbi HA, Bernatchez C, Forget MA, Haymkaer CL, Wong K, Tobin E, Benson MJ, Truppel-Hartmann A. A Phase 1/2 Study of KSQ-004EX: Autologous Tumor Infiltrating Lymphocytes, Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients with Select Advanced Solid Tumors. 2025 ASCO Annual Meeting.
205. Cho BC, Ahn MJ, Min Kim T, Kim SW, Han JY, Kim C, Yong Shim B, Ricordel C, Drilon AE, Pujol JL, Gray JE, Villaruz L, Blumenschein GR Jr., Liu K, Gillis K, Perez J, Tao W, Zhu O, Boyapati A, Lowy I, Kim E, Magnan H, Modi D. Prevalence and Concordance Analysis of MET Amplification/Overexpression in a Phase 1 Study of Davutamig (REGN5093) in a NSCLC. IASLC 2025 World Conference on Lung Cancer.
206. Zhang JJ, Zhu B, Salehjahromi M, Heeke S, Godoy M, Negrao MV, Vokes N, Le X, Pozadzides JV, Gay CM, Byers L, Cascone T, Tran HT, Lin SH, Carter B, Tam A, Rajaram R, Antonoff M, Ostrin E, Chen H, Blumenschein GR, Rice D, Walsh GL, Hofstetter W, Mehran RJ, Wu CC, Vaporciyan A, Zhang B, Araujo H, Moghaddam SJ, Wistuba I, Lee JJ, Wu J, Heymach JV. Canakinumab Interception Trial and Preclinical Studies Reveal Stage-Dependent Biology in Lung Cancer and Precancers. IASLC 2025 World Conference on Lung Cancer.

Book Chapters

1. Kies MS, Blumenschein Jr G R, Rosenthal D. Sequential Chemoradiation for Squamous Cell Carcinoma of the Head and Neck. In: ASCO 2008 Educational Book - Head and Neck Cancer: Hypothesis, Evidence, and Experience in Choosing Sequential Chemoradiation for Advanced Head and Neck Cancer, 235-38, 2008.
2. Blumenschein GR Jr. Treatment of Extensive Stage Small Cell Lung Cancer. In: M. D. Anderson Thoracic Oncology Monograph, 207-219, 2002.
3. Kies MS, Herbst RS, Blumenschein GR Jr. Head and Neck Cancer. In: The Cambridge Handbook of Advanced Cancer Care, 2001.
4. Ajani J, Blumenschein GR Jr. The Principles and Practice of Gastrointestinal Oncology. In: Oxford University Press, NYP 928, 2000.